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Melanoma is a life-threatening malignant disease, of which the standard of 
care treatment is rapidly becoming immunologically driven, due to favorable 
recent clinical trials using immune checkpoint inhibitors.  Diphencyprone 
(DPCP), a topically applied contact sensitizer, has been used with an 84% success 
rate to treat cutaneous melanoma metastases, but the immune mechanisms 
underlying its efficacy are largely unknown.  This thesis characterizes skin 
immune reactions induced by DPCP, both in healthy volunteers and patients with 
metastatic melanoma. 
In healthy volunteers, DPCP led to upgregulation of many immune 
molecules that may be anti-neoplastic effectors, including IFNγ, IL-24, and IL-9.  
We also examined the potential roles of miRNAs in skin reactions to DPCP, as 
they may be involved in its therapeutic applications, but are largely unstudied in 
skin biology and immunology.  Furthermore, we used comprehensive T cell 
receptor sequencing to show that the immune reactions induced by DPCP are 
polyclonal, and therefore suggests that the induced inflammation is not due to a 
single antigen.  Also, different individuals expanded different T cell clones in 
response to the same application of DPCP, which could mean that DPCP is 
conjugating with unique proteins in each person.  This may have relevance to the 
action of DPCP in melanoma patients, as each treated patient may expand a 
unique repertoire of T cells specific to antigens found only in that patient.  In sum, 
this work with healthy volunteers formed a basis for investigating specific 
immune elements that may be induced in melanoma lesions that are treated with 
DPCP, as well as the baseline immune competence of cancer patients.  It also led 
to insights regarding the regulation of immune responses, and provides a useful 
comparison point to inflammatory skin diseases such as psoriasis. 
Our clinical trial with metastatic melanoma patients allowed us to more 
directly study the immunologic mechanisms underlying the efficacy of DPCP to 
treat skin metastases.  Six patients enrolled in the study, and although each had a 
unique treatment course, 5 demonstrated at least partial melanoma regression in 
response to DPCP treatment.  In these patients, we observed a shift towards Th1 
polarization with the repeated DPCP applications required for treatment efficacy.  
This shift is likely relevant to melanoma treatment, as Th1 cells have established 
roles in anti-melanoma responses.  To further support this, one of our patients 
who had both a regressing and non-regressing metastasis in response to DPCP, 
had increased expression of Th1-defining molecules in the former.  A different 
patient, who received DPCP with checkpoint inhibitor therapy, provided proof of 
concept that these two immunotherapeutics can act synergistically.  Overall, this 
work provides varied insights into cutaneous immune responses, and how they 
can be successfully employed in the context of skin cancer therapy. 
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CHAPTER 1: INTRODUCTION 
Malignant Melanoma	  
Melanoma is a life-threatening malignant disease arising from melanocytes, the 
resident pigment-producing cells of the epidermis.  The lifetime risk of 
developing this disease has been increasing since the 1930s (Rigel et al. 2005).  In 
2015, 73,870 cases of invasive cutaneous melanoma are expected to be newly 
diagnosed, resulting in an estimated 9,940 deaths (SEER Cancer Statistics 
Review).  Although melanoma constitutes only 4 to 11 percent of all skin cancers, 
it is responsible for over 75 percent of skin cancer deaths (Netscher et al. 2011), 
thus highlighting the extreme health burden caused by this disease. 
Of paramount clinical consequence are melanoma lesions that metastasize to other 
organs, including the skin itself.  In primary lesions, the depth of invasion, or the 
distance from the superficial epidermal granular cell layer to the deepest 
intradermal tumor cells, known as the Breslow thickness, correlates with the 
probability of metastasis (Breslow 1980).  Despite increasing knowledge 
regarding its molecular mechanisms, metastatic melanoma is often limited in 
response to treatment (Chudnovsky et al. 2005), and the best predictor of eventual 
mortality remains depth of invasion as measured on a pathology slide.  Improved 
understanding of the biology of melanoma can be exploited to create targeted 
drugs and novel therapeutic approaches (Gray-Schopfer et al. 2007). 
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Although melanomas express many tumor-associated antigens, immune responses 
against them are often inefficient (Gajewski 2006).  Potential mechanisms for this 
include loss of expression of histocompatibility antigens on tumor cell surfaces, 
the production of immunosuppressive cytokines, the activation of regulatory T 
cells, and T cell exhaustion.  MLANA-specific T cells isolated from tumor-
infiltrated lymph nodes of melanoma patients had impaired IFNγ production and 
enrichment of the gene set (when compared to MLANA-specific cells from 
blood) which characterizes exhausted T cells (Baitsch et al. 2011).  Although 
exhausted T cells typify lymphocytes in or adjacent to melanoma lesions, these 
cells are capable of effector immune responses if negative checkpoints are 
antagonized or the cells are stimulated by other means. 
 
The inflammatory infiltrates of melanoma have been characterized in several 
studies, and the presence of tumor-infiltrating lymphocytes improves melanoma 
prognosis (Clemente et al. 1996).  The observed leukocyte infiltration in 
melanoma may be a side effect of the neoplastic cells stimulating themselves in 
an autocrine fashion, an innate anti-tumor response, or a combination of both of 
these along with other prospective explanations.  Immunotherapeutic approaches 
for melanoma, where host lymphocytes are set to kill melanoma cells, is of great 
interest in part because of the presumably immune-mediated spontaneous 
melanoma remissions which sporadically occur (McGovern 1975).  Also, vitiligo, 
a disease characterized by patchy depigmentation, is presumed to be due to 
autoimmune attack on melanocytes (Spritz 2012).  This attack appears relatively 
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specific to melanocytes, as other cell types in the skin are functionally normal, 
and therefore vitiligo highlights the capacity for the immune system to selectively 
target melanoyctes.  Excellent responses are sometimes obtained with 
immunotherapy (Hunder et al. 2008), but further work needs to be done to 
confirm the general applicability of such treatments. 
 
Immune checkpoint blockade, targeting cytotoxic T lymphocyte-associated 
antigen 4 (CTLA-4) or programmed cell death protein 1 (PD-1), is an emerging 
therapeutic avenue in a variety of cancer types, but most studied in and FDA 
approved for malignant melanoma (Postow et al. 2015a).  These therapies are 
antibodies targeted against negative immunologic regulators (checkpoints), 
effectively allowing for anti-melanoma immune responses to proceed with less 
interference.  Despite many very promising instances of tumor regression, on 
average only one-third of patients respond to these therapies when given alone, 
and these failures are thought to have a genetic basis (Snyder et al. 2014).  Tumeh 
et al. examined metastatic melanoma patients treated with the PD-1 inhibitor 
pembrolizumab, and demonstrated that tumor regression with this agent requires 
pre-existing CD8+ T cells that are negatively regulated by the PD-1/PD-L1 axis 
(Tumeh et al. 2014).  Very recently, the two agents targeting CTLA-4 and PD-1 
have been combined, and this dual approach resulted a 61% objective response 
rate, with a 22% complete response rate (Postow et al. 2015b).  Therefore, 
combination of multiple agents targeting the immune system is a viable 
therapeutic approach in malignant melanoma. 
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The melanoma treatment landscape has changed dramatically in the last 5 years, 
with several agents being approved by the FDA for metastatic melanoma 
treatment (Figure 1.1).  These include one agent targeting CTLA-4 (ipilimumab), 
one inhibiting a kinase (BRAF) commonly mutated in melanoma (vemurafenib), 
and two targeting PD-1 (pembrolizumab and nivolumab).  As a result, patients 
today have many promising options for treatment that were not available only 5 
years ago. 
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Figure 1.1: Timeline showing FDA approval of new agents for metastatic 
melanoma treatment.  Months when the FDA approved each drug are indicated 
above the timeline, and below the timeline are key events of the two clinical 
studies (one in healthy volunteers and one in melanoma patients) that make up 
this thesis. 
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Diphencyprone (DPCP)	  
 
Another emerging therapeutic approach in melanoma, also in the realm of 
immunotherapy, is the contact sensitizer diphencyprone (DPCP).  This sensitizer 
has recently been used in an Australian 50-patient case series of cutaneously 
metastatic melanoma, with 46% of patients having complete clearance of their 
disease and a further 38% having partial clearance (Damian et al. 2014) (Figure 
1.2), but is not currently FDA approved for any indication. 
 
Haptens like dinitrochlorobenzene and DPCP induce strong delayed-type 
hypersensitivity (DTH) recall reactions.  Upon first exposure, haptens penetrate 
the epidermis and then conjugate with endogenous proteins, leading to antigen 
formation.  The antigen is captured by antigen-presenting cells such as 
Langerhans cells, which mature and migrate to lymph nodes, where they clonally 
expand T cells specific for the antigen.  These clonally expanded cells then 
circulate, and the individual is sensitized.  Upon re-exposure, elicitation or 
challenge occurs, characterized by skin infiltration of the expanded T cells and 
resultant clinical inflammation (Figure 1.3).  Upregulation of an array of 
inflammatory cytokines occurs during a "peak" challenge response, which ranges 
from 2-4 days in human skin (Stute et al., 1981).  Hapten studies performed in 
mice have shown important roles for both CD4+ helper T cells and CD8+ 
cytotoxic T cells in the induction of DTH reactions (Saint-Mezard et al. 2005).  
Although alphabeta-T cells are the effector cells, NKT cells, B-1 cells, and 
gammadelta-T cells also play important roles in contact sensitivity DTH reactions  
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Figure 1.2: Regression of cutaneous melanoma metastases upon DPCP 
treatment.  This 71-year-old man presented with extensive, radiation-resistant 
recurrent scalp disease (A).  All cutaneous melanoma metastases regressed within 
4 weeks of starting DPCP (B), and five years later he remains disease free.  From 
(Damian et al. 2014). 
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Figure 1.3: Schematic of the sensitization and challenge phases of a DTH 
reaction.  (1) Haptens gain access to the skin through the viable epidermis. (2) 
Binding of haptens and endogenous skin proteins. (3) Langerhans cells bind to the 
hapten–protein complex and mature during migration to the lymph node. (4) 
Langerhans cells present haptenated protein to naïve T cells. (5) Clonal expansion 
of specific effector and memory T cells. (6) Proliferated T cells disseminate into 
the blood circulation, resulting in sensitization of an individual. (7) Re-exposure 
of similar haptens to the same individual. (8) Release of pro-inflammatory 
cytokines and chemokines by epidermal cells. (9) Infiltration of T cells from 
blood vessels into the site of contact. (10) Development of clinical inflammation.  
From (Wong et al. 2015). 
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(Askenase 2001).  Despite these and other murine studies which study haptens as 
prototypical causes of DTH reactions, the T cell polarization involved has shown 
conflicting results, with both Th1 and Th2 cells being variably implicated (Black 
1999). 
 
In human skin, T cell polarization as well as the cellular and molecular events 
associated with DTH responses are incompletely understood.  This is especially 
true if one considers that agents like dinitrochlorobenzene and DPCP have been 
used, somewhat paradoxically, to increase local immune responses for the 
resolution of warts (Upitis and Krol, 2002) and melanoma metastases (Damian et 
al., 2014), but also to decrease pathogenic immunity for the restoration of hair 
growth in alopecia areata (Freyschmidt-Paul et al., 2003).  One might postulate 
from these various therapeutic applications that cytotoxic effector immune 
pathways are induced by topical haptens, while activation of negative regulatory 
pathways also occurs to eventually down-regulate the inflammatory response.  
Available data from murine models suggest that resolution of cutaneous immune 
responses to haptens may be strongly dependent on regulatory T cells in the skin 
(Lehtimäki et al., 2012), leading to active mechanisms of immune suppression 
during the resolution phase of a DTH response.  In fact, negative regulatory 
immune mechanisms may be of more general importance for maintaining skin 
homeostasis as non-inflammatory in the face of a large population of effector 
memory T cells that normally reside in the skin (Clark et al., 2006).  The 
elimination of regulatory T cells from the skin has the consequence of increasing 
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skin inflammation due to environmental or chemical allergens in animal models 
(Freyschmidt et al., 2010)(Dudda et al., 2008).  The absence of negative 
regulatory mechanisms likely contributes to inflammatory skin diseases like 
psoriasis, where chronic activation of T cells and dendritic cells, with ongoing 
production of many inflammatory cytokines, leads to focal plaques of disease that 
rarely resolve spontaneously.  Cellular and molecular events associated with DTH 
responses to topical and intradermal antigens are much better understood for the 
sensitization and early elicitation phases (particularly the peak DTH reaction that 
occurs within 4 days of recall exposure), compared to later phases of the 
elicitation response when negative regulatory pathways might be dominant 
(Vocanson et al., 2009).  Very little is known about immune cellular elements and 
expression of negative regulatory immune molecules during this resolution phase 
in humans. 
 
In this thesis, two clinical studies involving human subjects are presented.  First, a 
study with healthy volunteers was undertaken to examine DTH reactions induced 
by a single application of DPCP, including the T cell polarization involved and 
potential anti-neoplastic mechanisms.  Second, a treatment protocol with 
metastatic melanoma patients was completed, this time employing repeated 
applications of DPCP as was done in the Australian trial (Damian et al. 2014).  
The goal of this treatment protocol was to examine immune mechanisms 
associated with melanoma metastasis regression induced by DPCP. 
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CHAPTER 2: MATERIALS AND METHODS 	  
Study subjects and skin samples – healthy volunteers 
Skin biopsies were obtained from 11 volunteers under a protocol approved by The 
Rockefeller University’s Institutional Review Board.  Written, informed consent 
was obtained from all subjects and the study adhered to the Declaration of 
Helsinki Principles.  All volunteers underwent a rigorous screening process, 
including medical history, physical examination, complete blood count/blood 
chemistries, and point-of-care HIV test to ensure they were overall healthy and 
not on any medication which could interfere with immune reactions.  Each 
volunteer was sensitized to 0.4% DPCP (in a topical gel formulation) on his/her 
right upper arm and 0.04% DPCP on his/her left lower arm.  These concentrations 
were chosen to ensure effective sensitization while minimizing uncomfortable 
inflammatory reactions on the arms.  Previous work has demonstrated that 0.4% 
but not 0.04% DPCP is consistently able to induce sensitization in 
immunocompetent individuals (Levis et al., 2006).  Two weeks later, effective 
sensitization was confirmed by noting induration at the application sites (all 
subjects were successfully sensitized) and then two challenge applications of 
0.04% DPCP were applied to the subject’s left upper thigh.  Also at this visit, two 
placebo applications (identical formulation but without DPCP) were applied to the 
subject’s right upper thigh.  Each application of placebo or DPCP gel was 0.2 mL 
(80 µg for the 0.04% concentration) placed on a 2.5 x 2.5 cm square area bandage 
which the subject was instructed to leave on for 24 hours before removal and 
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washing.  Three days after these challenge applications, one 6 mm full thickness 
punch biopsy was taken of a DPCP-treated site and an identical biopsy was taken 
of a placebo-treated site (day 3 biopsies).  Subjects were then observed at 7 and 
14 days post-challenge to determine when the DPCP-induced inflammation was 
resolving, based on clinical scoring of erythema and induration.  At that time (14 
days post-challenge), another pair of biopsies was taken, but of the two sites not 
biopsied at 3 days post-challenge (Figure 2.1).  Six of 11 volunteers were brought 
back 4-8 months after challenge application for another biopsy of a DPCP-treated 
site, which clinically no longer exhibited any signs of inflammation.  Ultrasound 
images were acquired using DermaScan C ultrasound scanner (Cortex 
Technology, Hadsund, Denmark).  In these images, dermal inflammation is 
visualized as a dark zone (brackets) under epidermis and the thickness of this 
zone correlates with the extent of inflammation/induration (Kelly et al., 
1998)(Hoffmann et al. 1994a). 
 
Study subjects and skin samples – psoriasis patients 
For psoriatic lesional vs. non-lesional skin microarray data, we used the meta-
analysis derived (MAD3) transcriptome as previously described (Tian et al. 
2012).  Psoriatic lesional tissue for qRT-PCR and immunohistochemistry studies 
were from deidentified residual samples of plaque-type psoriasis vulgaris from 
previous studies for whom no clinical characteristics are available; a psoriasis 
area severity index of more than 12 (moderate-to-severe psoriasis vulgaris with 
>10% body surface area involvement) was required for entry into these trials. 
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Figure 2.1:  Schematic of DPCP sensitization and challenge schedule.  
Subjects were sensitized with DPCP at two sites on their arms at Day 0 followed 
by challenge and placebo applications at Day 14.  At Day 17 (3 days post-
challenge), one pair of biopsies was taken and a second pair was taken at Day 28 
(14 days post-challenge) when the inflammation induced by DPCP was seen to be 
clinically resolving.  Dark green, light green, and blue squares indicate 
sensitization, challenge, and placebo applications, respectively.  A red X is used 
to represent a biopsy taken. 
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Study subjects and skin samples – melanoma patients 
Skin biopsies were obtained from melanoma patients with cutaneous metastases 
under a protocol approved by The Rockefeller University’s Institutional Review 
Board.  Written, informed consent was obtained and the study adhered to the 
Declaration of Helsinki Principles.  The patients all underwent rigorous screening 
processes, including medical history, physical examination, and point-of-care 
HIV test to ensure that they did not have any conditions and were not on any 
medications which could interfere with immune reactions.  While enrolled in our 
DPCP trial at The Rockefeller University, all patients continued to receive their 
standard oncologic follow-up and monitoring visits. 
 
Patients were sensitized to 0.4% DPCP (in the same topical gel formulation as 
used with the healthy volunteers) on one of their cutaneous metastases and their 
right upper arm, as well as to 0.04% DPCP (also in a topical gel formulation) on 
their left lower arm.  Two weeks later, effective sensitization was confirmed by 
noting induration at the application sites, and then challenge applications were 
applied to the subject’s cutaneous metastases.  Also at this visit, one 0.2 mL 
application of 0.4% DPCP was applied to one area of non-melanoma skin, and 
another 0.2 mL application of 0.04% DPCP was applied to a different area of non-
melanoma skin.  These two applications were completed in order to determine the 
concentration of DPCP that would induce tolerable inflammation in each patient, 
so that the appropriate concentration could be used for challenge (treatment) 
applications.  For all patients, one of the inflamed non-melanoma sites challenged 
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with DPCP was biopsied 3 days later (the classical time of “peak” response to a 
single application of DPCP).  Each application of DPCP (occurring twice weekly) 
was self-administered by the patient such that all cutaneous metastases were 
covered with a thin layer of gel (the patient was asked to return the tube 
containing the DPCP gel at each clinic visit for weighing in order to ensure 
compliance), and then covered with Tegaderm for at least 2 hours. 
 
All biopsies (6 mm full thickness punch) were bisected: one half was immediately 
placed in RNAlater RNA Stabilization Reagent (Qiagen, Valencia, CA) for later 
RNA extraction, and the other half was frozen in optimum cutting temperature 
(OCT) compound (Thermo Fisher Scientific Inc., Wilmington, DE) for later 
histological sectioning. 
 
RNA extraction, quantification, and microarray 
Total RNA was extracted using the miRNeasy Mini Kit (Qiagen, Valencia, CA) 
according to the manufacturer’s protocol with on-column DNase digestion.  The 
amount of RNA was assessed by NanoDrop 1000 spectrophotometer (Thermo 
Fisher Scientific Inc., Wilmington, DE).  The quality of extracted RNA was 
examined using Agilent Bioanalyzer 2100 (Agilent Technologies, Palo Alto, CA).  
RNA was hybridized to HGU133 Plus 2.0 chips (Affymetrix, Santa Clara, CA) to 
measure relative gene expression. 
 
 
 16	  
Statistical analysis of microarray data 
Microarray data were analyzed using R/Bioconductor packages (http://www.r-
project.org).  The Harshlight package (Suárez-Fariñas et al., 2005) was used to 
scan Affymetrix chips for spatial artifacts.  Expression values were obtained using 
the GCRMA algorithm.  Genes with low variation and low expression in most 
samples were filtered out prior to the analysis.  Batch effect due to hybridization 
date was adjusted using ComBat (Johnson et al., 2007).  Principal Components 
Analysis (PCA) was used to represent the high dimensionality of the data along 
the directions of maximal variance.  Hypotheses of interest were tested using 
contrasts in R’s limma package framework.  The p values resultant from the 
moderated paired Student’s t-tests were adjusted for multiple hypotheses using the 
Benjamini-Hochberg procedure, which controls for the false discovery rate.  
Ingenuity Pathway Analysis (www.ingenuity.com) was used to determine 
canonical pathways significantly linked to various gene sets. 
 
Quantitative RT-PCR 
Pre-amplification quantitative RT-PCR technique was used for measuring various 
genes in total RNA extracted from skin biopsy samples according to the 
company’s instructions.  Briefly, 5 ng of total RNA was subjected to first-strand 
cDNA synthesis using High Capacity cDNA Reverse Transcription kits (Applied 
Biosystems, Carlsbad, CA).  The resulting cDNA was subjected to 14 cycles of 
pre-amplification using TaqMan PreAmp Master Mix Kit (Applied Biosystems) 
with desired pooled assay mix.  The Gene Amp PCR System 9700 (Applied 
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Biosystems) was used for the pre-amplification reaction with the following 
thermal cycler conditions: 10 min at 95oC and 14 cycles of 15 seconds at 95oC 
followed by 4 min at 60oC.  12.5 µl of pre-amplified cDNA was then used for 
quantitative RT-PCR reaction using TaqMan Gene Expression Master Mix 
(Applied Biosystems).  The 7900HT Fast Real-Time PCR System was used for 
PCR reactions, and the thermal cycler conditions were as follows: 2 minutes at 
50oC, 5 minutes at 95oC, and 40 cycles of 15 seconds at 95oC followed by 60 
seconds at 60oC.  Data were analyzed by the Applied Biosystems PRISM 7700 
software (Sequence Detection Systems, ver. 1.7) and normalized to human acidic 
ribosomal protein (hARP) housekeeping gene.  All assays were from Applied 
Biosystems except for RPLP0/hARP, where a custom primer/probe set was used 
(Forward: CGCTGCTGAACATGCTCAA, Reverse: 
TGTCGAACACCTGCTGGATG, Probe: 6-FAM-
TCCCCCTTCTCCTTTGGGCTGG-TAMRA). 
 
For miRNA studies, individual qRT-PCR assays were used to validate the 
expression levels of miR-21, -7, -503 and -383 using the TaqMan MicroRNA 
Reverse Transcription Kit (Applied Biosystems) followed by PCR using TaqMan 
MicroRNA assays (Applied Biosystems).  Samples were analyzed using the 
7900HT sequence detection system (Applied Biosystems) according to the 
manufacturer’s directions.  The qRT-PCR data were processed using the ∆∆CT 
method in order to obtain expression fold changes (Schmittgen and Livak 2008), 
with RNU6B used as the reference gene. 
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Immunohistochemistry 
Frozen sections of skin biopsies were dried at room temperature and then fixed 
for 2 minutes in acetone.  Next, the samples were blocked with 10% normal 
serum of the species in which the secondary antibody was made and then the 
samples were incubated overnight at 4oC with the appropriate primary antibody.  
Biotin-labeled secondary antibodies (Vector Laboratories, Burlingame, CA) were 
amplified with avidin-biotin complex (Vector Laboratories) and developed with 
chromogen 3-amino-9-ethylcarbazole (Sigma Aldrich, St. Louis, MO) to produce 
a red color indicative of positive staining.  The number of positive cells per mm 
was counted manually per field using computer-assisted image analysis (NIH 
Image 6.1; http://rsb.info.nih.gov/nih-image). 
 
Immunofluorescence 
Frozen sections of skin biopsies were dried at room temperature and then fixed 
with acetone.  Next, the samples were blocked with 10% normal goat serum 
(Vector Laboratories) for 30 minutes.  Primary antibody was incubated overnight 
at 4oC and amplified with the appropriate secondary antibody for 30 minutes.  For 
co-localization, sections were then co-stained overnight with a second antibody, 
and amplified with the appropriate secondary antibody for 30 minutes.  Images 
were acquired using the appropriate filters of a Zeiss Axioplan 2 wide-field 
fluorescence microscope (Thornwood, NY) with a Plan Neofluar 20 × 0.7 
numerical aperture lens and a Hamamatsu Orca Er-cooled charge-coupled device 
 19	  
camera (Bridgewater, NJ), controlled by METAVUE software (MDS Analytical 
Technologies, Downington, PA).  Images in each figure are presented both as 
single-color stains (green and red) located above the merged image, so that 
localization of two markers on similar or different cells can be appreciated.  Cells 
that co-express the two markers in a similar location are yellow in color.  A white 
line denotes the dermoepidermal junction.  Dermal collagen fibers gave green 
autofluorescence, and antibodies conjugated with a fluorochrome often gave 
background epidermal fluorescence. 
 
miRNA sequencing and statistical analysis 
Barcoded small RNA sequencing was performed using a modified version of an 
established protocol (Hafner et al. 2008).  Briefly, 100 ng total RNA from each 
sample was subjected to 3’ and 5’ adapter ligation and RT-PCR amplification.  
The resulting cDNA library was sequenced using Illumina sequencing technology 
(Illumina, Inc., San Diego, CA).  The bioinformatic analysis of the small RNA 
sequence data was performed as described previously (Farazi et al. 2012).  
Barcodes were used to mark individual samples so that up to 20 could be 
processed simultaneously (Hafner et al. 2012). 
 
Sequence data were imported into the R working environment (www.r-
project.org) and analysed using the edgeR package from Bioconductor 
(http://bioconductor.org).  edgeR supports differential expression analysis and is 
based on a negative binomial distribution.  It adjusts any differential expression 
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analysis for varying sequencing depths as represented by differing library sizes 
(Robinson et al. 2010).  Only human miRNAs complying with a threshold of 100 
sequence reads per miRNA in a minimum of 50% of the samples within each 
group were included in the further analysis.  Unsupervised principal component 
analysis (PCA) and Pearson’s correlation analysis were applied to explore the 
association between the samples.  False discovery rate < 0.05 was considered as 
statistically significant. 
 
DNA extraction and T cell receptor (TCR) sequencing 
For each biopsy specimen frozen in OCT, 40 sections were cut at 10 micron 
thickness and then processed for DNA extraction using the QIAamp DNA Mini 
Kit (Qiagen). DNA samples were shipped on dry ice to Adaptive Biotechnologies 
(Seattle, WA) for survey level immunosequencing using the immunoSEQ human 
TCRB assay.  
 
Immunosequencing was performed by first completing multiplex PCR to capture 
the highly variable CDR3 region. A synthetic immune repertoire was used to 
iteratively measure and subsequently correct for amplification bias. Then, high-
throughput sequencing was done to exclusively target T cell receptor genes. Data 
analysis was performed by Adaptive Biotechnologies.	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CHAPTER 3: HISTOLOGICAL AND GENE EXPRESSION 
PROFILING OF HEALTHY VOLUNTEER SKIN 
REACTIONS TO DIPHENCYPRONE 
 
Kinetics of skin inflammation induced by DPCP 
Healthy individuals (demographics listed in Table 3.1) were sensitized to DPCP 
and two weeks later received two challenge applications on their left thigh and 
two placebo applications on their right thigh.  Three days after challenge, all 
subjects exhibited strong clinical inflammation (erythema, induration, and 
epithelial vesiculation in some cases) only in DPCP-treated sites, whereas 
placebo-treated sites were indistinguishable from background skin (Figure 3.1).  
The clinical DPCP-induced reaction was clearly diminished by 14 days after the 
challenge dose.  Erythema and induration were quantified using a 0-4 scale 
derived from the Psoriasis Area Severity Index (PASI).  The mean response at day 
3 was 5.5 (for sum of erythema and induration) and was reduced to 2.1 by day 14 
(p<10-7) (Table 3.1).  Ultrasound measurements further confirmed a decrease in 
dermal inflammation over time (Figure 3.1).  Overall, these data support the 
classical view that 3 days after challenge represents the clinical peak of a DTH 
response. 
 
Kinetics of cellular and molecular immune response to DPCP in DTH 
reactions 
Biopsies were taken of both DPCP- and placebo-treated sites at day 3 (clinical 
peak) and at day 14 (resolving inflammation).  The first 6 patients also  
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Table 3.1: Demographics and clinical scoring of inflammatory reactions 
induced by DPCP in all subjects (n=11) 
Subject 
ID Gender Age Race Subgroup day 31 day 141 
day 3 
score 
day 14 
score 
001 M 55 White B 4/4 (1.19) 2/1 (0.20) 8 3 
006 M 52 Black A 2/2 (0.30) 0/1 (0.18) 4 1 
008 F 42 Asian B 3/2 (0.66) 1/1 (0.19) 5 2 
009 M 58 White B 2/2 (0.21) 1/0 (0.18) 4 1 
012 M 44 White A 3/2 (0.30) 2/1 (0.10) 5 3 
013 F 46 Black A 3/3 (0.76) 2/1 (0.36) 6 3 
014 M 20 Asian A 3/3 (0.36) 2/0 (0.15) 6 2 
015 M 55 Black B 2/2 (0.21) 1/0 (0.12) 4 1 
016 F 29 Black A 3/1 (0.24) 1/0 (0.18) 4 1 
020 M 43 Black B 3/3 (0.87) 1/1 (0.24) 6 2 
021 M 40 Black B 4/4 (1.51) 2/2 (0.24) 8 4 
Average             5.5 2.1 
p = 7.8 x 10-8 for DPCP day 3 vs day 14 score comparison (paired two-tailed 
Student's t-test). 
1Erythema/induration (0-4 scale for each) - scores are sums of these two 
measures.  In parentheses are the quantifications of the extent of inflammation as 
measured by ultrasound (in mm, see Figure 3.1). 
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Figure 3.1:  Visualization of inflammatory reactions induced by DPCP over 
time.  Clinical photography with ultrasound imaging below of a skin site (a) 
treated with placebo, (b) 3 days after treatment with DPCP, (c) 7 days after 
treatment with DPCP, and (d) 14 days after treatment with DPCP.  Brackets on 
ultrasound images indicate extents of inflammatory reactions as reflected by 
dermal thickness.  Shown is a representative subject (subject 008). 
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underwent skin biopsies of reaction sites 4 to 8 months after DPCP challenge (late 
biopsy).  In the acute response, T cells appeared rapidly at DTH challenge sites 
with a mean of 1,113 CD3+ T cells/mm of skin.  Overall, T cell counts 
diminished slightly by day 14, with a mean of 946 cells/mm.  In late biopsies, T 
cells were reduced to levels seen in placebo sites (<100/mm).  Relative to placebo 
and generally expected, increases were seen in CD3+ and CD8+ lymphocytes 
(Figure 3.2a and b), as well as in dendritic cell (DC) populations in the day 3 and 
day 14 biopsies, but two patterns of response were seen with cellular infiltrates as 
will be discussed in the next section.  T cell activation in biopsies was assessed by 
RT-PCR measures of mRNAs that are associated with specific T cell subsets, e.g., 
IFNγ defining a Th1 response, IL-13 defining a Th2 response, or IL-17 defining a 
Th17 response (Figure 3.2c).  Marked increases in cytokine mRNA levels 
occurred in day 3 DPCP-treated sites, with changes ranging from 9-fold to >1000-
fold (log2 3.2 to >10 as graphed in Figure 3.2c).  The day 14 reactions showed 
reduced expression of each T cell subset cytokine with the largest declines in IL-9 
and IL-13.  All cytokine levels normalized in late biopsies (Figure 3.2c).  The day 
3 DPCP response was also associated with a 6-fold increase in forkhead box P3 
(Foxp3) mRNA, but this product did not diminish on average in day 14 biopsies.  
Overall, visible skin inflammation in the DPCP reaction at days 3 and 14 was 
better correlated with levels of pro-inflammatory cytokine mRNAs than with the 
number of infiltrating T cells or DCs.  The diminishing production of 
inflammatory cytokine mRNAs at day 14 with persistence of Foxp3 expression 
suggests the possibility of an altered positive vs. negative regulatory immune 
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Figure 3.2:  Reactions to DPCP include immune activation markers that are 
present at day 3 but diminish over time.  (a, b) Immunohistochemistry for CD3 
(a) and CD8 (b) on placebo-treated samples, DPCP day 3 samples, DPCP day 14 
samples, and DPCP late samples.  Scale bar = 100 µm.  (c) RT-PCR analysis for 
IFNG, IL2, IL2RA, IL13, IL9, IL17A, IL22, and Foxp3.  Shown are average 
normalized expression values for placebo-treated day 3 samples (light blue bars, 
n=11), placebo-treated day 14 samples (dark blue bars, n=11), DPCP day 3 
samples (pink bars, n=11), DPCP day 14 samples (red bars, n=11), and DPCP-
treated samples 4-8 months after challenge (late) (brown bars, n=6).  Asterisks 
indicate p<0.01 when compared to placebo and error bars represent standard 
errors of the mean.  (d) Principal components analysis (PCA) of microarray data 
showing all samples as individual dots colored according to sample type.  The 
larger dots are averages for each sample type. 
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balance in day 3 vs. day 14 reactions. 
 
Molecular profiling of day 3 and day 14 DPCP responses 
To profile the global set of gene expression changes in the DPCP reactions, skin 
biopsies were hybridized to Affymetrix HGU133 2.0 Plus arrays.  A principal 
components analysis (PCA) of the skin responses is diagrammed in Figure 3.2d.  
Day 3 DPCP reactions were widely separated from placebo responses in the major 
axis of variation (PCA-1), whereas the day 14 reactions approached the placebo 
sites and late biopsies overlapped completely with placebo responses.  Using 
cutoffs of false discovery rate<0.05 and fold change>2, the day 3 DTH responses 
had 3,670 upregulated and 3,884 downregulated probe sets compared to placebo-
treated skin.  Tables 3.2 and 3.3 list the top ten up-regulated and down-regulated 
genes, respectively, in day 3 and day 14 reactions.  Since the "top" gene sets are 
largely different at day 3 vs. day 14, the tables are constructed with a listing of 
gene expression for both sets of genes at both day 3 and day 14.  Among genes 
with the highest induction at day 3, granzyme B (119-fold increase) and IL-24 
(107-fold increase) are molecules with identified roles in tissue rejection or anti-
neoplastic control of melanomas or other cancers.  Strong expression of CXCL10 
(104-fold increase) and CXCL9 (85-fold increase) suggest activation of STAT1-
regulated genes by IFNγ production.  At day 14, the genes with highest expression 
at day 3 were strongly down-regulated (on average >10-fold), with IL-24 
expression reduced to background levels in placebo-treated skin.  In the day 14  
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Table 3.2: Top 10 up-regulated genes in DPCP day 3 and DPCP day 14 vs 
placebo samples 
 
Gene Description fold 
change at 
day 3 
fold  
change at 
day 14 
(a) top up-regulated transcripts at day 3   
SERPINB4 serpin peptidase inhibitor, clade B 
(ovalbumin), member 4 
340.5 10.6 
S100A7A S100 calcium binding protein A7A 170.9 6.1 
DEFB4A defensin, beta 4A 169.5 17.0 
MMP1 matrix metallopeptidase 1 (interstitial 
collagenase) 
167.3 4.9 
MMP12 matrix metallopeptidase 12 
(macrophage elastase) 
147.9 8.4 
GZMB granzyme B (granzyme 2, cytotoxic T-
lymphocyte-associated serine esterase 
1) 
118.8 11.2 
IL24 interleukin 24 106.8 1.3 
CXCL10 chemokine (C-X-C motif) ligand 10 104.2 25.5 
S100A9 S100 calcium binding protein A9 97.7 15.7 
APOBEC3A apolipoprotein B mRNA editing 
enzyme, catalytic polypeptide-like 3A 
95.0 1.2 
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(b) top up-regulated transcripts at day 14   
CXCL9 chemokine (C-X-C motif) ligand 9 84.7 37.3 
COL6A6 collagen, type VI, alpha 6 11.0 36.1 
CCL18 chemokine (C-C motif) ligand 18 
(pulmonary and activation-regulated) 
15.0 32.1 
CXCL10 chemokine (C-X-C motif) ligand 10 104.2 25.5 
SERPINB3 serpin peptidase inhibitor, clade B 
(ovalbumin), member 3 
68.0 23.3 
COL6A5 collagen, type VI, alpha 5 15.8 20.1 
CD1B CD1b molecule 10.5 19.6 
DEFB4A defensin, beta 4A 169.5 17.0 
S100A9 S100 calcium binding protein A9 97.7 15.7 
OASL 2'-5'-oligoadenylate synthetase-like 54.5 12.1 
(c) regulatory genes with selective expression in  
day 14 samples 
  
ARG1 arginase, liver 0.2 11.6 
FLT3 fms-related tyrosine kinase 3 2.5 11.5 
XCR1 chemokine (C motif) receptor 1 0.3 6.1 
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Table 3.3: Top 10 down-regulated genes in DPCP day 3 and DPCP day 14 vs 
placebo samples 
Gene Description fold 
change at 
day 3 
fold 
change at 
day 14 
(a) top down-regulated transcripts at day 3     
IL37 interleukin 37 -46.0 -2.3 
ATP1A2 ATPase, Na+/K+ transporting, alpha 2 
polypeptide 
-38.3 -3.2 
GDF10 growth differentiation factor 10 -36.4 -3.2 
SGCG sarcoglycan, gamma (35kDa dystrophin-
associated glycoprotein) 
-29.8 -4.4 
MYOC myocilin, trabecular meshwork inducible 
glucocorticoid response 
-29.2 -7.1 
VIT vitrin -26.8 -2.7 
DPP6 dipeptidyl-peptidase 6 -25.6 -3.2 
THRSP thyroid hormone responsive -24.9 -3.4 
DLG2 discs, large homolog 2 (Drosophila) -23.7 -1.4 
FIBIN fin bud initiation factor homolog (zebrafish) -23.4 -4.7 
(b) top down-regulated transcripts at day 14   
WIF1 WNT inhibitory factor 1 -6.2 -27.1 
GALNTL2 UDP-N-acetyl-alpha-D-
galactosamine:polypeptide N-
-2.1 -9.9 
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acetylgalactosaminyltransferase-like 2 
RBP4 retinol binding protein 4, plasma -10.8 -8.2 
BTC betacellulin -19.8 -8.1 
LEP leptin -7.2 -8.0 
TNMD tenomodulin -10.2 -7.8 
MYOC myocilin, trabecular meshwork inducible 
glucocorticoid response 
-29.2 -7.1 
MUC7 mucin 7, secreted -5.6 -6.1 
IL17D interleukin 17D -13.6 -6.1 
SPINK1 serine peptidase inhibitor, Kazal type 1 -3.4 -5.9 
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biopsies, CCL18 was amplified from the day 3 response and CD1b also became 
more strongly expressed, likely corresponding to increased DCs at this time point. 
 
The only genes common in top up-regulated products between day 3 and day 14 
were defensin beta 4, CXCL10, and S100A9.  On a more global level, of the 793 
up-regulated and 726 down-regulated probesets at day 14, 317 were uniquely 
expressed at day 14 and not day 3 (Figure 3.3a), illustrating that the overall 
transcriptomic response is distinct between these two time points and that day 14 
reactions are not simply an intermediate between day 3 and placebo responses.  
These unique genes at day 14 included arginase, liver (ARG1), fms-related 
tyrosine kinase 3 (FLT3), and chemokine, C motif, receptor 1 (XCR1) (Table 
3.2c, confirmatory immunohistochemistry and immunofluorescence to co-localize 
with CD11c+ DCs in Figure 3.3b and c), all of which may play roles in immune 
response resolution.  In terms of genes that were down-regulated in the DPCP 
response (Table 3.3), we noted that the day 3 and day 14 responses were largely 
distinct, as with up-regulated genes.  The top down-regulated gene at day 3 was 
IL-37, which is known to negatively regulate inflammatory responses and where 
~20-fold increased expression at day 14, relative to day 3, could represent an 
active regulatory mechanism.  A full list of genes that are up-regulated or down-
regulated in day 3 and day 14 biopsies is available on request and all microarray 
data have been deposited in a public database.  Granulysin was also highly 
upregulated (47-fold) and appeared in mononuclear leukocytes in the dermis at 
days 3 and 14.  To localize cells producing granulysin, two color  
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Figure 3.3:  DPCP day 14 reactions include many unique genes and XCR1+ 
DCs not present in day 3 reactions.  (a) Venn diagram showing up- and down-
regulated probesets (red and green, respectively) in day 3 and day 14 reactions.  
(b) Immunohistochemistry for XCR1 and (c) immunofluorescence for XCR1 
(red)/CD11c (green) on representative placebo-treated (left), DPCP day 3 
(middle) and DPCP day 14 (right) samples.  Scale bar = 100 µm. 
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immunofluorescence was performed.  The strongest co-localization with 
granulysin was CD3+ T cells, with some but not all CD8+ cells staining for this 
cytolytic effector molecule.  A few CD11c+ dendritc cells also appeared to 
produce granulysin (Figure 3.4). 
 
Immune infiltrates follow two distinct patterns after a DPCP challenge 
In all patients, we measured marked increases in CD3+ T cells and CD11c+ DCs 
in day 3 “peak” reactions.  However, we detected two distinct reaction patterns 
for the day 14 “resolution” reaction.  One pattern seen in 5/11 patients (subgroup 
A, Figure 3.5) showed increasing numbers of T cells and/or DCs in the day 14 
biopsies compared to the day 3 reactions, a response that was entirely unexpected 
(Figure 3.5c and d).  This subset of patients also showed even larger increases in 
mature (DC-LAMP+) DCs in day 14 biopsies compared to day 3 biopsies, and 
this subgroup had the most pronounced dermal infiltrates of Langerin+ cells 
(Figure 3.5e and f).  However, the expression of inflammation-associated 
cytokines and CD25 (IL-2RA) usually decreased in day 14 biopsies compared to 
day 3 reactions, so we detected a disassociation between cellular immune 
infiltrates and production of inflammatory cytokines/activation molecules (Figure 
3.5a).  As further evidence for this, both CD3+ and CD11c+ cell counts did not 
significantly correlate with gene expression levels of any of the following 
immune activation markers: IFNγ, IL-2, and IL-2RA (Figure 3.6).  The other 
response pattern seen in 6/11 patients (subgroup B, Figure 3.7) fit the expected 
response kinetics for a DTH reaction: T cell and DC infiltrates peaked at day 3  
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Figure 3.4:  Granulysin co-localizes with CD3+ (both CD8+ and CD8-) and 
CD11c+ cells.  Immunofluorescence staining of granulysin with (a) CD3 (green), 
(b) CD8 (red), and (c) CD11c (red).  Left panels are placebo-treated samples, 
middle panels and DPCP day 3 samples, and right panels are DPCP day 14 
samples.  Shown is a representative subject (subject 013).  Scale bar = 100 µm. 
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Figure 3.5:  RT-PCR and histological analysis of subjects whose CD3+ or 
CD11c+ infiltrates increase from 3 days to 14 days post-DPCP challenge 
(subgroup A, n=5).  (a) RT-PCR analysis for IFNγ (left panel), IL-2 (middle 
panel), and IL-2RA (right panel).  Shown are normalized expression values for 
each subject individually to highlight that almost all samples have decreased 
expression of these genes at day 14 compared to day 3.  (b-f) H&E (b) and 
immunohistochemical analysis of samples for (c) CD3, (d) CD11c, (e) DC-
LAMP, and (f) Langerin.  For all histological images, left panels show placebo 
reactions, middle panels show DPCP day 3 reactions, and right panels show 
DPCP day 14 reactions.  Shown is a representative subject (subject 013).  For 
immunohistochemical stains, line graphs indicate subgroup-wide average cell 
counts for placebo, DPCP day 3, DPCP day 14, and DPCP late samples.  
Asterisks indicate p<0.05 when compared to placebo.  Scale bar = 100 µm. 
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Figure 3.6:  Correlations of immunohistochemistry cell counts with immune 
activation markers by RT-PCR.  Shown are scatter plots of (a) CD3+ and (b) 
CD11c+ cell counts with normalized gene expression measures of IFNγ (top), IL-
2 (middle), and IL-2RA (bottom).  Only DPCP day 3 and day 14 samples are 
plotted.  p-values for all correlations were >0.27 so none reached statistical 
significance. 
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Figure 3.7:  RT-PCR and histological analysis of subjects whose CD3+ or 
CD11c+ infiltrates decrease from 3 days to 14 days post-DPCP challenge 
(subgroup B, n=6).  (a) RT-PCR analysis for IFNγ (left panel), IL-2 (middle 
panel), and IL-2RA (right panel).  Shown are normalized expression values for 
each subject individually to highlight that almost all samples have decreased 
expression of these genes at day 14 compared to day 3.  (b-f) H&E (b) and 
immunohistochemical analysis of samples for (c) CD3, (d) CD11c, (e) DC-
LAMP, and (f) Langerin.  For all histological images, left panels show placebo 
reactions, middle panels show DPCP day 3 reactions, and right panels show 
DPCP day 14 reactions.  Shown is a representative subject (subject 015).  For 
immunohistochemical stains, line graphs indicate subgroup-wide average cell 
counts for placebo, DPCP day 3, DPCP day 14, and DPCP late samples.  
Asterisks indicate p<0.05 when compared to placebo.  Scale bar = 100 µm. 
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and were significantly reduced at day 14 (p = 0.01 and 0.001, respectively).  As in 
subgroup A, expression of inflammatory cytokines and activation molecules was 
decreased in resolution biopsies. 
 
Subjects whose infiltrates decrease from day 3 to day 14 have higher levels of 
negative regulatory cells and molecules at day 3 
We performed immunofluorescence for Foxp3 with CD3 to more specifically 
identify regulatory T cells, which were then quantified as Foxp3+CD3+ cells.  On 
average, subjects in subgroup B had more Tregs than those in subgroup A at day 3 
(21.25 versus 9) (Figure 3.8a and b).  We also performed RT-PCR for several 
known downregulatory molecules.  For all molecules tested (IL-10, lymphocyte 
activation gene 3 (LAG3), programmed cell death 1 (PD1), programmed cell 
death ligand (PDL) 1, PDL2, indoleamine 2,3-dioxygenase (IDO1), and CTLA4), 
mRNA levels were higher at day 3 in subgroup B than subgroup A.  Also, there 
were non-significant but consistent trends for subjects in subgroup B to have 
higher levels of these molecules even in placebo-treated skin, suggesting baseline 
immunological differences between subjects in the two subgroups (Figure 3.8c-i).  
On a more global level, when looking at a comprehensive list of negative 
regulator genes (Table 3.4 has “negative regulator” list, curated through Gene 
Ontology term 0002683 “negative regulation of immune system process” and 
literature review, and expression values for DPCP day 3, as well as psoriasis to be 
discussed in the next section), subjects in subgroup B had higher expression of   
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Figure 3.8:  Negative regulatory immune cells and molecules are increased in 
DPCP day 3 reactions of subgroup B compared to subgroup A.  (a, b) Foxp3 
(red)-CD3 (green) immunfluorescence for (a) a representative subgroup A 
member (subject 012) and (b) a representative subgroup B member (subject 021).  
Left panels are DPCP day 3 samples and right panels are DPCP day 14 samples.  
Regulatory T cells were quantified as double-positive for Foxp3 and CD3.  
Subject 012 had 4 double-positive cells at day 3 (subgroup-wide average of 9) and 
24 at day 14 (subgroup wide average of 20.33) while subject 021 had 37 at day 3 
(subgroup-wide average of 21.25) and 19 at day 14 (subgroup-wide average of 
12).  (c-i) RT-PCR analysis for (c) IL-10, (d) CTLA4, (e) PD1, (f) PDL1, (g) 
PDL2, (h), IDO1, and (i) LAG3.  Shown are average normalized expression 
values of placebo day 3, placebo day 14, DPCP day 3, and DPCP day 14 skin for 
both subgroups (n=5 for subgroup A (blue bars), n=6 for subgroup B (green 
bars)).  p-values are shown to compare subgroup A with subgroup B for each 
sample type.  Scale bar = 100 µm. 
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Table 3.4: Expression of negative regulator genes in DPCP day 3 vs. placebo 
and psoriasis lesional vs. non-lesional skin samples 
   
  
DPCP day 3 
  
  
psoriasis 
  
Probe Symbol Description FCH p FDR FCH p FDR 
207526_s_at IL1RL1 interleukin 1 receptor-like 1 42.8 5.3E-11 2.1E-09 1.1 3.6E-03 1.3E-02 
227458_at CD274 CD274 molecule 34.6 1.9E-12 1.3E-10 23.7 0.0E+00 0.0E+00 
236341_at CTLA4 
cytotoxic T-lymphocyte-associated protein 
4 21.6 3.7E-11 1.5E-09 3.7 6.0E-02 1.4E-01 
207238_s_at PTPRC 
protein tyrosine phosphatase, receptor type, 
C 18.0 1.6E-12 1.2E-10 2.6 0.0E+00 0.0E+00 
206341_at IL2RA interleukin 2 receptor, alpha 17.9 4.7E-14 6.3E-12 1.3 1.6E-01 2.9E-01 
210146_x_at LILRB2 
leukocyte immunoglobulin-like receptor, 
subfamily B (with TM and ITIM domains), 
member 2 12.5 3.6E-08 5.4E-07 2.9 0.0E+00 0.0E+00 
222062_at IL27RA interleukin 27 receptor, alpha 12.3 9.9E-13 7.6E-11 1.3 1.7E-03 6.7E-03 
217192_s_at PRDM1 PR domain containing 1, with ZNF domain 11.1 8.7E-12 4.6E-10 3.0 0.0E+00 0.0E+00 
215719_x_at FAS Fas (TNF receptor superfamily, member 6) 9.3 7.8E-07 7.6E-06 1.1 2.8E-02 7.6E-02 
205926_at IL27RA interleukin 27 receptor, alpha 8.3 5.9E-11 2.3E-09 1.2 1.3E-01 2.4E-01 
204780_s_at FAS Fas (TNF receptor superfamily, member 6) 8.0 2.6E-05 1.6E-04 1.1 1.3E-01 2.4E-01 
242743_at IL4R interleukin 4 receptor 8.0 7.6E-13 6.2E-11 1.1 6.0E-02 1.4E-01 
242809_at IL1RL1 interleukin 1 receptor-like 1 6.6 1.5E-06 1.3E-05 1.0 7.6E-01 8.3E-01 
207697_x_at LILRB2 
leukocyte immunoglobulin-like receptor, 
subfamily B (with TM and ITIM domains), 
member 2 6.6 1.2E-13 1.4E-11 1.5 0.0E+00 0.0E+00 
212588_at PTPRC 
protein tyrosine phosphatase, receptor type, 
C 6.5 2.8E-08 4.3E-07 2.4 0.0E+00 0.0E+00 
216252_x_at FAS Fas (TNF receptor superfamily, member 6) 6.3 9.4E-08 1.2E-06 1.1 7.0E-04 2.9E-03 
230052_s_at NFKBID 
nuclear factor of kappa light polypeptide 
gene enhancer in B-cells inhibitor, delta 6.2 1.0E-07 1.3E-06 1.4 1.4E-02 4.3E-02 
211336_x_at LILRB1 
leukocyte immunoglobulin-like receptor, 
subfamily B (with TM and ITIM domains), 
member 1 5.2 4.8E-16 1.5E-13 1.3 2.3E-03 8.7E-03 
212587_s_at PTPRC protein tyrosine phosphatase, receptor type, 5.1 6.5E-13 5.5E-11 1.8 2.2E-03 8.3E-03 
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C 
207104_x_at LILRB1 
leukocyte immunoglobulin-like receptor, 
subfamily B (with TM and ITIM domains), 
member 1 5.1 3.0E-17 1.6E-14 1.2 0.0E+00 0.0E+00 
211269_s_at IL2RA interleukin 2 receptor, alpha 5.1 2.8E-08 4.4E-07 1.1 1.8E-01 3.1E-01 
204781_s_at FAS Fas (TNF receptor superfamily, member 6) 4.7 3.4E-06 2.7E-05 1.2 3.6E-02 9.3E-02 
1552480_s_at PTPRC 
protein tyrosine phosphatase, receptor type, 
C 4.5 9.0E-08 1.2E-06 1.0 3.3E-01 4.7E-01 
203233_at IL4R interleukin 4 receptor 4.4 1.2E-10 4.0E-09 3.9 0.0E+00 0.0E+00 
206060_s_at PTPN22 
protein tyrosine phosphatase, non-receptor 
type 22 (lymphoid) 4.3 7.6E-06 5.5E-05 2.3 1.0E-04 4.0E-04 
223834_at CD274 CD274 molecule 3.8 5.7E-09 1.1E-07 1.5 3.6E-03 1.3E-02 
235458_at HAVCR2 hepatitis A virus cellular receptor 2 3.8 6.6E-07 6.6E-06 1.5 1.4E-03 5.5E-03 
231794_at CTLA4 
cytotoxic T-lymphocyte-associated protein 
4 3.4 1.6E-09 3.7E-08 1.2 6.4E-02 1.4E-01 
227900_at CBLB 
Cbl proto-oncogene, E3 ubiquitin protein 
ligase B 3.3 1.8E-04 8.3E-04 0.8 9.6E-03 3.1E-02 
220418_at UBASH3A 
ubiquitin associated and SH3 domain 
containing A 3.3 3.0E-05 1.8E-04 1.1 2.7E-02 7.3E-02 
202643_s_at TNFAIP3 
tumor necrosis factor, alpha-induced 
protein 3 3.2 1.0E-08 1.8E-07 1.2 1.9E-01 3.2E-01 
240070_at TIGIT 
T cell immunoreceptor with Ig and ITIM 
domains 3.0 2.9E-05 1.8E-04 1.3 4.2E-02 1.0E-01 
201537_s_at DUSP3 dual specificity phosphatase 3 3.0 4.8E-11 1.9E-09 1.5 0.0E+00 0.0E+00 
228964_at PRDM1 PR domain containing 1, with ZNF domain 2.9 3.4E-06 2.7E-05 3.0 0.0E+00 0.0E+00 
201538_s_at DUSP3 dual specificity phosphatase 3 2.9 3.6E-10 1.1E-08 1.3 2.5E-01 3.8E-01 
203236_s_at LGALS9 lectin, galactoside-binding, soluble, 9 2.7 3.5E-07 3.8E-06 1.6 0.0E+00 0.0E+00 
224399_at PDCD1LG2 programmed cell death 1 ligand 2 2.7 1.3E-07 1.7E-06 1.0 1.6E-01 2.8E-01 
241889_at NFKBID 
nuclear factor of kappa light polypeptide 
gene enhancer in B-cells inhibitor, delta 2.6 6.5E-06 4.8E-05 1.0 8.8E-02 1.9E-01 
223506_at ZC3H8 zinc finger CCCH-type containing 8 2.6 5.6E-04 2.2E-03 1.6 0.0E+00 0.0E+00 
209744_x_at ITCH itchy E3 ubiquitin protein ligase 2.6 3.8E-07 4.1E-06 2.8 1.4E-02 4.1E-02 
225622_at PAG1 
phosphoprotein associated with 
glycosphingolipid microdomains 1 2.6 3.4E-05 2.0E-04 1.9 0.0E+00 0.0E+00 
217094_s_at ITCH itchy E3 ubiquitin protein ligase 2.4 1.1E-05 7.8E-05 2.4 6.9E-02 1.5E-01 
224211_at FOXP3 forkhead box P3 2.4 1.2E-05 7.9E-05 1.0 0.0E+00 1.0E-04 
243196_s_at TRAFD1 TRAF-type zinc finger domain containing 1 2.3 4.0E-05 2.3E-04 0.9 4.8E-01 6.1E-01 
228996_at RC3H1 ring finger and CCCH-type domains 1 2.3 5.5E-05 3.0E-04 1.8 2.5E-01 3.9E-01 
219364_at DHX58 
DEXH (Asp-Glu-X-His) box polypeptide 
58 2.3 5.3E-07 5.4E-06 1.3 0.0E+00 0.0E+00 
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202763_at CASP3 
caspase 3, apoptosis-related cysteine 
peptidase 2.2 1.8E-05 1.1E-04 1.1 1.1E-01 2.2E-01 
236539_at PTPN22 
protein tyrosine phosphatase, non-receptor 
type 22 (lymphoid) 2.2 6.9E-05 3.7E-04 2.0 0.0E+00 0.0E+00 
202644_s_at TNFAIP3 
tumor necrosis factor, alpha-induced 
protein 3 2.2 1.4E-06 1.3E-05 1.1 2.8E-01 4.2E-01 
205298_s_at BTN2A2 butyrophilin, subfamily 2, member A2 2.2 3.7E-04 1.6E-03 1.1 1.9E-01 3.2E-01 
217513_at MILR1 mast cell immunoglobulin-like receptor 1 2.1 6.0E-06 4.4E-05 1.2 5.9E-02 1.4E-01 
205299_s_at BTN2A2 butyrophilin, subfamily 2, member A2 2.0 3.9E-05 2.2E-04 1.1 1.1E-01 2.2E-01 
242497_at TRAFD1 TRAF-type zinc finger domain containing 1 1.8 4.1E-04 1.7E-03 1.0 6.3E-01 7.4E-01 
234066_at IL1RL1 interleukin 1 receptor-like 1 1.8 7.5E-03 2.0E-02 1.0 3.6E-01 5.1E-01 
235668_at PRDM1 PR domain containing 1, with ZNF domain 1.8 3.0E-06 2.4E-05 2.2 0.0E+00 0.0E+00 
1555628_a_at HAVCR2 hepatitis A virus cellular receptor 2 1.8 6.7E-04 2.6E-03 1.0 4.3E-01 5.6E-01 
209682_at CBLB 
Cbl proto-oncogene, E3 ubiquitin protein 
ligase B 1.8 6.1E-05 3.3E-04 0.8 0.0E+00 0.0E+00 
209354_at TNFRSF14 
tumor necrosis factor receptor superfamily, 
member 14 1.8 3.2E-06 2.6E-05 1.0 7.1E-01 8.0E-01 
227354_at PAG1 
phosphoprotein associated with 
glycosphingolipid microdomains 1 1.7 7.0E-02 1.3E-01 1.3 3.7E-02 9.4E-02 
209743_s_at ITCH itchy E3 ubiquitin protein ligase 1.7 4.4E-03 1.3E-02 1.2 0.0E+00 0.0E+00 
35254_at TRAFD1 TRAF-type zinc finger domain containing 1 1.7 1.7E-05 1.1E-04 0.9 2.8E-01 4.1E-01 
1555629_at HAVCR2 hepatitis A virus cellular receptor 2 1.7 2.4E-04 1.1E-03 1.0 7.6E-01 8.4E-01 
202837_at TRAFD1 TRAF-type zinc finger domain containing 1 1.6 5.5E-05 3.0E-04 1.0 9.1E-01 9.4E-01 
235057_at ITCH itchy E3 ubiquitin protein ligase 1.6 2.7E-02 6.0E-02 0.9 2.0E-01 3.3E-01 
1554285_at HAVCR2 hepatitis A virus cellular receptor 2 1.6 5.4E-04 2.2E-03 1.0 1.5E-01 2.7E-01 
225626_at PAG1 
phosphoprotein associated with 
glycosphingolipid microdomains 1 1.5 2.3E-02 5.2E-02 1.3 6.0E-04 2.5E-03 
201536_at DUSP3 dual specificity phosphatase 3 1.5 3.2E-04 1.4E-03 0.8 0.0E+00 1.0E-04 
1553042_a_at NFKBID 
nuclear factor of kappa light polypeptide 
gene enhancer in B-cells inhibitor, delta 1.5 3.0E-03 9.4E-03 1.1 2.6E-02 7.1E-02 
220049_s_at PDCD1LG2 programmed cell death 1 ligand 2 1.4 5.4E-03 1.5E-02 1.0 4.3E-01 5.7E-01 
221331_x_at CTLA4 
cytotoxic T-lymphocyte-associated protein 
4 1.3 4.8E-04 2.0E-03 1.1 4.7E-02 1.1E-01 
234362_s_at CTLA4 
cytotoxic T-lymphocyte-associated protein 
4 1.3 4.6E-03 1.3E-02 1.1 1.2E-01 2.4E-01 
208010_s_at PTPN22 
protein tyrosine phosphatase, non-receptor 
type 22 (lymphoid) 1.3 2.4E-03 7.8E-03 1.1 4.0E-04 1.7E-03 
234895_at CTLA4 
cytotoxic T-lymphocyte-associated protein 
4 1.1 4.9E-02 9.7E-02 1.0 2.0E-04 8.0E-04 
225893_at RC3H1 ring finger and CCCH-type domains 1 1.1 7.0E-01 7.8E-01 1.0 3.6E-01 5.0E-01 
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224859_at CD276 CD276 molecule 0.9 4.4E-01 5.6E-01 0.9 2.0E-04 9.0E-04 
236235_at ITCH itchy E3 ubiquitin protein ligase 0.8 2.6E-01 3.7E-01 0.7 3.6E-03 1.3E-02 
239101_at ITCH itchy E3 ubiquitin protein ligase 0.7 1.5E-02 3.6E-02 0.7 0.0E+00 0.0E+00 
1559583_at CD276 CD276 molecule 0.6 8.5E-02 1.5E-01 1.0 3.2E-01 4.6E-01 
219768_at VTCN1 
V-set domain containing T cell activation 
inhibitor 1 0.3 8.1E-05 4.2E-04 0.6 2.2E-03 8.6E-03 
204472_at GEM 
GTP binding protein overexpressed in 
skeletal muscle 0.3 1.1E-05 7.6E-05 1.0 3.0E-01 4.4E-01 
FCH, fold change; FDR, false discovery rate. 
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many of these molecules at day 3 (Figure 3.9).  These data may help explain why 
subgroup B had decreased cellular infiltrates at day 14, and suggest that different 
individuals resolve their inflammatory responses to DPCP with different kinetics 
(inflammation resolution was faster in subgroup B, based on ultrasound measures 
at days 7 and 14, Figure 3.10). 
 
Psoriasis is characterized by deficient negative immune regulation compared 
to transient DTH reactions induced by DPCP 
Since DTH reactions naturally resolve, we sought to compare our DPCP biopsies 
to those taken from patients with psoriasis vulgaris (Tian et al. 2012), a chronic T 
cell-mediated inflammatory disease that does not resolve and which, in many 
ways, represents amplifications of background immune circuits that exist in 
normal human skin (Lowes et al. 2014).  To globally assess the balance of 
positive vs. negative immune regulators in both DPCP reactions and psoriasis 
using our microarray data, we developed a comprehensive gene list for positive 
regulatory or inflammatory genes and used our previously described negative 
regulatory or immunosuppressive gene list (Table 3.4 has the “negative 
regulator” list and fold change values for DPCP day 3 and psoriasis 
transcriptomes, “positive regulator” list is derived from Gene Ontology term 
0002684 “positive regulation of immune system process” but with genes removed 
that are in common with Gene Ontology term 0002683 “negative regulation of 
immune system process”).  Our microarray data showed increased fold changes of 
many negative regulators in DPCP day 3 biopsies vs placebo-treated skin (DPCP  
 49	  
 
 
Figure 3.9:  Subjects in subgroup B globally have more negative regulatory 
genes at day 3 than subjects in subgroup A.  Heat map of negative regulatory 
genes for all DPCP samples.  Each column represents one sample arranged first 
by subgroup then by sample type with there being 5 subjects in subgroup A and 6 
in subgroup B.  DPCP day 3 samples are highlighted as underneath the black bars. 
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Figure 3.10: Subjects in subgroup B show resolution of clinical inflammation 
more quickly than subjects in subgroup A.  Plots of ultrasound measurements 
of extents of inflammatory reactions as reflected by dermal thickness (see Figure 
3.1) versus time for subjects in subgroup A (top) and subjects in subgroup B 
(bottom).  Each subject is shown as an individual line. 
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day 3 transcriptome) compared to psoriasis lesional vs non-lesional skin (psoriasis 
transcriptome).  For instance, CTLA4 expression was significantly increased 
21.6-fold in the DPCP day 3 transcriptome, but non-significantly increased 3.7-
fold in the psoriasis transcriptome.  Venn diagrams show that the psoriasis 
transcriptome only has seven genes from the negative regulator list, while the 
DPCP day 3 transcriptome has 52 (Figure 3.11a).  Although the DPCP day 3 
transcriptome also has more genes from the positive regulator list than psoriasis, 
the odds ratio for the positive regulator list was not significantly different between 
these two transcriptomes.  The odds ratio for the negative regulator list, however, 
was significantly different (Figure 3.11b).  The altered balance between positive 
vs. negative regulatory transcripts in psoriasis compared to DPCP reactions can 
also be seen in Figure 3.11c which shows that DPCP transcriptomes at all time 
points (days 3, 14, and 120) have higher ratios of negative to positive regulator 
genes than the psoriasis transcriptome in terms of expression levels for each gene 
set as a whole (as opposed to number of genes as indicated in the Venn diagrams).  
This is despite the fact that the DPCP day 3 transcriptome has comparable 
expression levels of the MAD3 psoriasis transcriptome genes to actual psoriasis 
samples, and therefore highlights the negative regulator expression that is unique 
to DPCP reactions. 
 
To confirm some of our microarray findings, we performed qRT-PCR and found 
that psoriasis lesional skin biopsies have significantly lower expression of many    
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Figure 3.11: Psoriasis lesional skin has an altered global balance of positive 
vs. negative regulatory gene transcripts compared to DPCP reactions. (a) 
Venn diagrams showing overlap of MAD3 psoriasis transcriptome (left) and 
DPCP day 3 transcriptome (right) with both positive regulatory (Pos) and 
negative regulatory (Neg) gene lists (common gene lists applied to both 
transcriptomes).  The percentages of the MAD3 and DPCP day 3 transcriptomes 
comprised of the positive regulatory gene list are 5.7% and 7.3%, respectively.  
On the other hand, the percentages comprised of the negative regulatory gene list 
are 0.7% and 1.5%, respectively.  (b) Odds ratios (OR) of negative regulatory (red 
bars) and positive regulatory (blue bars) gene lists in DPCP day 3 and psoriasis 
transcriptomes.  (c) Black bars represent negative regulator genes, gray bars 
represent positive regulator genes, and white bars represent all MAD3 psoriasis 
transcriptome genes.  The y-axis shows log2 (fold change) of all genes in the given 
gene set.  DPCP day 3 and MAD3 samples have comparable MAD3 
transcriptome expression levels but there is a substantial difference between all 
DPCP time points (days 3, 14, and 120 or “late”) and MAD3 samples in terms of 
the relative levels of negative and positive regulator gene list expression.  This is 
quantified as the “ratio of negative to positive regulator genes.” 
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negative immune regulators compared to peak DPCP biopsies.  These regulators 
include LAG3, CTLA4, IDO1, PD1, PDL1, PDL2, and IL-10 (Figure 3.12a).  
We confirmed the decreased expression of these and FAS (which by gene 
expression had 9.3- and 1.1-fold changes in the DPCP day 3 and psoriasis 
transcriptomes, respectively) at the protein level by immunohistochemistry 
(Figure 3.12b). 
 
Discussion 
This study with DPCP provides, to our knowledge, the first detailed cellular and 
molecular phenotype of a DTH response at both peak and resolution stages.  The 
strong clinical response at day 3 was accompanied by large increases in 
infiltrating T cells and myeloid DCs, as well as by differential regulation (>2 fold 
change) of 7,555 gene transcripts.  The resolution phase was characterized by 
variable changes in infiltrating leukocytes, overall increased in subgroup A and 
decreased in subgroup B compared to the peak reaction.  In molecular terms, the 
resolution phase showed decreased expression of T cell effector cytokines and 
molecules associated with the activation phase of immune responses, but 
relatively higher levels of transcripts associated with negative regulation of 
immune responses.  Also, the resolution phase included expression of certain 
genes including ARG1, XCR1, and FLT3 that were not present during the peak 
response.  ARG1 has been shown to lead to reversible blocks in T cell 
proliferation (Bronte et al., 2003), XCR1 contributes to regulatory T cell 
development (Lei et al., 2011), and FLT3 is involved in maintaining the balance  
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Figure 3.12: Psoriasis lesional skin has lower expression of various negative 
immune regulators than DPCP day 3 reactions by both qRT-PCR and 
immunohistochemical approaches. (a) qRT-PCR analysis for negative 
regulators LAG3, CTLA4, IDO1, PD1, PDL1, PDL2, and IL10.  Shown are 
average normalized expression values for DPCP day 3 samples (n=11, purple 
bars) and psoriasis lesional skin (LS) samples (n=11, brown bars).  All except 
PDL1 are p<0.05 by unpaired two-tailed t-test assuming equal variance.  Error 
bars represent standard errors of the mean.  (b) Immunohistochemistry showing 
increased protein expression of negative regulators in DPCP day 3 samples 
compared to psoriasis LS.  Shown are stains with antibodies specific to the 
indicated targets.  Scale bar = 100 µm. 
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between DC and regulatory T cell numbers (Liu and Nussenzweig, 2010).  
Although we chose to characterize the immune response to DPCP in normal 
human skin, our results identify immune mechanisms that may relate to the use of 
DPCP as an immune modulator in treatment of melanoma or alopecia areata. 
 
In a recent report, 50 patients with cutaneous metastases of melanoma were 
treated with repeated application of DPCP.  Forty-six percent of patients had 
complete regression of their lesions and a further 38 percent had partial responses, 
but corresponding study of the immune response to DPCP was not conducted 
(Damian et al., 2014).  The potential of DPCP as an adjuvant to improve 
immunotherapy has been demonstrated in mice (Moos et al. 2012).  Several 
immune pathways that we found to be induced by DPCP in normal skin might 
mediate this anti-melanoma response.  First, we identified significant up-
regulation of IL-24 mRNA, which is a cytokine with established anti-melanoma 
activity (Jiang et al., 1995).  Since this cytokine was up-regulated only transiently 
(peak at day 3, but resolved at day 14), it could indicate the need for 
chronic/repeated application of DPCP to maintain effector cytokines for tumor 
responses.  Furthermore, we observed strong increases in IFNγ expression and 
this cytokine enhances antigen presentation potential, is anti-proliferative for 
many cell types (Braumüller et al., 2013), and its induced molecule CXCL10 has 
anti-melanoma activity (Antonicelli et al., 2011).  Another cytokine we found to 
be upregulated by DPCP, IL-9, has recently been linked to melanoma regression 
(Purwar et al., 2012).  In addition to these cytokines with potential anti-neoplastic 
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effects, DPCP use resulted in many infiltrating CD8+ cells, along with increased 
granzyme B and granulysin expression, and these would be probable cytotoxic 
effectors.  Granulysin has been shown to promote chemotaxis of CD4+ T cells in 
addition to its cytolytic properties (Deng et al., 2005), and both of these functions 
may contribute to the peak DTH response considering we observed granulysin 
expression on both CD8+ and CD8- T cells.  We also noted a marked increase in 
DCs and especially DC-LAMP+ mature DCs, that could provide a local 
environment to increase antigen presentation of tumor antigens (immature DCs, in 
the absence of appropriate co-stimulation, present antigens in a tolerogenic 
fashion), as well as XCR1+ DCs, which have a role in antigen cross-presentation 
(Kroczek and Henn, 2012).  Overall, this work forms a basis for investigating 
specific immune elements that may be induced in melanoma lesions that are 
treated with DPCP as well as the baseline immune competence of cancer patients. 
 
Many different reports have shown that 50-60% of patients with patchy alopecia 
areata have meaningful hair regrowth when treated with chronic application of 
DPCP (Freyschmidt-Paul et al., 2003)(Ohlmeier et al., 2012).  A smaller number 
of studies have been conducted to investigate immune alterations induced in the 
scalp that is associated with hair regrowth.  Identified effects of DPCP include 
decreasing CD4+ T cell but increasing CD8+ T cell infiltrates (Simonetti et al., 
2004).  Also, MHC class II expression has been shown to be altered by DPCP 
treatment in different studies, with both increases (Hunter et al., 2011) and 
decreases (Bröcker et al., 1987) having been demonstrated.  Furthermore, DPCP 
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alters the cytokine profile in treated alopecic scalp, in particular increasing IL-2 
and IL-10 expression (Hoffmann et al. 1994b).  This increased IL-10 expression 
has been hypothesized to inhibit the lesional T cells of alopecia areata, and our 
data confirm an upregulation of IL-10 expression, as well as increases in CD8+ T 
cells, in normal human skin treated with DPCP.  Our data also suggested roles for 
various other regulatory molecules in the response to DPCP whose potential 
relevance to alopecia areata treatment have not yet been elucidated.  However, our 
data do not directly inform on the potential effects of DPCP on scalp tissue, as 
well as alterations which may arise from repeated applications. 
 
We compared our findings on DPCP with those published on a DTH reaction to 
purified protein derivative (PPD) (Tomlinson et al., 2011).  The reaction to DPCP 
at 3 days compared to placebo-treated skin largely encompasses genes that are 
induced by a specific antigen (PPD in this case, 48 hours after exposure compared 
to 6 hours) (Figure 3.13).  Of genes that were upregulated in the reactions, 780 
were common to PPD and DPCP, but each agent also had unique upregulated 
genes.  Overall there was significant correlation with differentially expressed 
genes (r=0.61, p<10-16) and a gene set enrichment analysis for genes regulated in 
the PPD reaction had a normalized enrichment score of >4.0, indicating highly 
similar modulation of gene sets.  The analysis of the PPD data by Tomlinson et al. 
emphasized the polar Th1 nature of immune reactions, which is supported by 
measured increases in IFNγ mRNA, STAT1, and many other interferon-regulated  
 60	  
 
Figure 3.13:  Comparison of DPCP day 3 vs placebo day 3 reactions to PPD 
48 hr vs 6 hr reactions (data from (Tomlinson et al., 2011)).  Venn diagram 
shows 1,187, 780, and 1,017 upregulated genes uniquely in DPCP, in both DPCP 
and PPD, and uniquely in PPD, respectively (downregulated gene numbers are 
1,690, 24, and 112).  Tables underneath Venn diagram show selected genes from 
each section of the Venn diagram. 
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gene products.  Without measurement of cytokine production by more sensitive 
techniques, it is a bit uncertain if other “polar” T-cell subsets are significantly 
activated by PPD.  However, the DPCP response clearly showed activation of all 
defined “polar” T-cell subsets, i.e., Th1, Th2, Th9, Th17, and Th22, based on 
cytokine mRNA measures by RT-PCR.  Ingenuity Pathway Analysis significantly 
linked the canonical pathways of “IL-10 Signaling,” “Interferon Signaling,” “IL-6 
Signaling,” and “IL-17 Signaling” to the set of genes upregulated in both DPCP 
and PPD reactions.  All of these pathways except for “Interferon Signaling” were 
also significantly linked to the set of genes uniquely upregulated in DPCP 
reactions.  We feel the system provided here provides a valuable human model for 
studying DTH reactions, particularly as one does not need to select a subset of 
antigen-reactive individuals from a larger subset of non-immunized or non-
reactive individuals.  Also, our system with DPCP controls sensitization and 
therefore fixes the amount of time between initial antigen exposure and challenge 
reaction, unlike many alternative antigens. 
 
In contrast to soluble protein antigens, haptens derivatize with proteins that are 
present in the skin and may thus be present for longer time periods.  Hence, 
different response kinetics might be expected for hapten-induced DTH reactions 
than PPD reactions.  In this study, we did identify an expected inflammatory 
reaction in the skin that was strong at 3 days after DPCP exposure and T cell 
activation, as judged by specific markers (IFNγ, IL-2, and IL-2RA) as well as 
other activation-associated molecules, was highest at this time point.  However, 
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much to our surprise, T cell infiltrates persisted for much longer than expected 
based on the PPD model, and 5/11 patients showed increased numbers of T cells 
or DCs at day 14 compared to day 3.  Also, the number of mature (DC-LAMP+) 
DCs peaked at day 14 in 7/11 patients.  Certainly these data establish a 
disassociation between T cell activation/cytokine production and the magnitude of 
the cellular immune response defined by the number of T cells and DCs in the 
skin.  Therefore, the possibility of active negative regulatory mechanisms to 
suppress T cell activation to a potentially long-lived cutaneous antigen is 
suggested by these data. 
 
Overall, understanding the active mechanisms present during the resolution of 
responses to DPCP could have implications not only for cell-mediated immunity 
in general, but also for other skin pathologies of either chronic immune activation 
or ineffective immune responses.  Most importantly, this system could provide a 
tractable human antigen-specific model system for primary discovery of new 
pathways that may be involved specifically in immune regulation in peripheral 
tissues.  Since all T cell subsets become activated by in vivo DPCP, this system 
might also have utility to test mechanism/pharmacodynamic actions of new 
immune modulators designed to selectively inhibit “polar” T-cell subsets or 
activated T cells.  For example, there has recently been great interest in selective 
blockade of IL-17 for the treatment of psoriasis and IL-4 for the treatment of 
atopic dermatitis.  As these and many other key cytokines are activated by DPCP, 
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this system can be used to test a variety of pharmacologic agents targeted against 
pathogenic immune molecules. 
 
Our data comparing DPCP reactions to psoriasis suggest that disease chronicity in 
psoriasis could be related to absence of several negative immune regulatory 
pathways, and have the implication that strategies to obtain stable 
clearance/restore tolerance in skin lesions may need to focus on increasing these 
negative pathways.  These negative immune mechanisms may be of more general 
importance for maintaining skin homeostasis as non-inflammatory in the presence 
of a large population of effector memory T cells that normally reside in skin 
(Clark et al. 2006).  In addition, these negative immune regulators are likely 
involved in the therapeutic applications of DPCP, particularly alopecia areata 
where IL-10 has already been implicated (Hoffmann et al. 1994b).  Further study 
of these regulatory mechanisms that are present in DPCP reactions, but not in 
psoriasis, could reveal novel factors in the pathogenesis of chronic inflammation. 
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CHAPTER 4: miRNA PROFILING OF HEALTHY 
VOLUNTEER SKIN REACTIONS TO DIPHENCYPRONE 
 
We expanded our previous histological and gene expression profiling of healthy 
volunteer DPCP reactions to microRNA (miRNA) profiling.  miRNAs are short 
(19-24 nucleotide) endogenous, non-protein coding RNAs that negatively regulate 
gene expression at the post-transcriptional level.  They do this by sequence-
specific base pairing, typically within the 3’-untranslated region of the target 
mRNA, resulting in transcript cleavage or translational repression.  By current 
estimates, more than 60% of human protein-coding genes contain miRNA target 
sites (Friedman et al. 2009), and are therefore potentially regulated by miRNAs 
either physiologically or in disease.  Since individual miRNAs target multiple, 
functionally related (as opposed to single) genes, they are of great interest from a 
therapeutic perspective (Sayed and Abdellatif 2011).  The potential of modulating 
miRNA activity in a dermatological disease was recently demonstrated by 
Guinea-Viniegra et al., who showed that inhibition of miR-21 leads to 
amelioration of psoriasis pathology (Guinea-Viniegra et al. 2014).  However, the 
roles of most miRNAs in skin biology and immunology are only recently being 
characterized (Baltimore et al. 2008). 
 
Despite a number of studies on the involvement of miRNAs in inflammatory skin 
diseases such as psoriasis, previous work on the role of miRNAs in DTH 
inflammatory reactions is limited.  Vennegaard et al. have previously shown by 
microarray and PCR approaches that miRs-21, -142-3p, -142-5p, and -223 are 
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significantly upregulated in DPCP-challenged human skin as well as mouse skin 
challenged with a similar hapten, dinitrofluorobenzene (Vennegaard et al. 2012).  
However, this study only examined peak reactions and therefore does not inform 
on potential immunoregulatory mechanims during a resolving DTH reaction.  We 
obtained comprehensive miRNA expression profiles of DPCP challenge reactions 
at three different time points via deep sequencing to better understand mRNA 
regulation in DPCP responses over time, and how they may be involved in 
potential anti-melanoma effects. 
 
To define miRNA expression profiles of DPCP reactions, we used the same RNA 
samples from which mRNA expression data were obtained.  Comprehensive 
miRNA expression profiles were generated through barcoded small RNA 
sequencing.  By unsupervised principal component analysis (PCA), there was no 
miRNA separation due to gender, age, or race (volunteer demographics and 
clinical scoring of DPCP-induced inflammation provided in Table 3.1).  DPCP 
challenge biopsies, both at 3 days and 14 days, were clearly separated from 
placebo-treated skin, with the day 3 samples having a more distinct miRNA 
expression profile.  The DPCP challenge biopsies taken at day 120 clustered with 
placebo-treated samples.  Both of these sample types also clustered with normal 
skin samples taken from a separate study, therefore confirming that placebo-
treated skin and DPCP challenge biopsies taken at 120 days (both of which 
clinically appear normal) are similar to normal skin (Figure 4.1a).  This was 
further supported by a sample correlation matrix analysis, which showed a strong  
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Figure 4.1: Unique miRNA expression profiles in DPCP reactions at different 
times. (a) Principal component analysis (PCA) of global miRNA data for DPCP-
treated skin at times indicated, placebo-treated skin, and normal skin.  Heat maps 
of day 3 (b) and day 14 (c) samples.  Ordinate shows individual volunteers treated 
with placebo or DPCP and abscissa displays individual miRNA expression levels.  
(d) Venn diagrams showing overlaps of significantly upregulated (left) and 
downregulated (right) miRNAs at the three time points post-challenge: 3 days, 14 
days, and 120 days. 
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correlation across the normal appearing skin samples compared with DPCP days 
3 and 14 samples (Figure 4.2).  In fact, there were no significantly deregulated 
miRNAs between normal skin samples and placebo-treated skin.  Compared to 
placebo-treated skin, we found 127 significantly deregulated miRNAs at day 3 
after DPCP challenge and 43 at day 14 after challenge (Figure 4.1b and c).  
Table 4.1 lists the top 10 upregulated miRNAs at days 3 and 14.  There were 6 
significantly deregulated miRNAs at day 120 (all upregulated, fold changes in 
parentheses): miR-193a-3p (4.01), -136-5p (3.79), -377 (2.67), -140-5p (2.29), -
376c (2.19), -17 (2.12). 
 
Although the lists of top upregulated miRNAs at days 3 and 14 have several 
miRNAs in common, each of the three time points studied has a unique miRNA 
profile.  For instance, of the 69 upregulated miRNAs at day 3, only 25 are also 
upregulated at day 14.  Figure 4.1d provides Venn diagrams showing overlaps of 
significantly deregulated miRNAs at the three time points.  One miRNA in 
particular, miR-140-5p, increased in expression over time, with fold changes 
increasing from 1.92 to 2.25 to 2.29 from day 3 to 14 to 120.  We used qRT-PCR 
analysis to corroborate selected miRNA expression changes found by deep 
sequencing.  miRNA-21, one of the top upregulated miRNAs at both days 3 and 
14, as well as a novel potential therapeutic target in psoriasis (Guinea-Viniegra et 
al. 2014), was also found to be upregulated at both of these time points by qRT-
PCR analysis (fold changes of 1.9 and 5.4, respectively; P<0.005 for both).  miR-
7 and miR-503, both among the top 10 upregulated miRNAs at day 3, were also  
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Figure 4.2:  Correlation matrix analysis showing all samples.  Three-digit 
numbers indicate subject IDs (see Table 3.1) except for the two normal skin 
samples, which came from a separate study. 
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Table 4.1: Top 10 upregulated miRNAs in DPCP day 3 and DPCP day 14 
samples vs placebo-treated skin 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abbreviations: FDR, false discovery rate; RF, read frequencies. 
microRNA fold change p-value FDR Total RF 
(a) top upregulated miRNAs at day 3 
hsa-miR-223     20.87 0.00 0.00 252065 
hsa-miR-150     15.71 0.00 0.00 519815 
hsa-miR-21*     15.20 0.00 0.00 25877 
hsa-miR-142-5p  14.45 0.00 0.00 224392 
hsa-miR-142-3p  14.26 0.00 0.00 153335 
hsa-miR-7-2     12.79 0.00 0.00 5941 
hsa-miR-7-1     12.69 0.00 0.00 6128 
hsa-miR-7-3     12.69 0.00 0.00 5839 
hsa-miR-503     9.37 0.00 0.00 6563 
hsa-miR-150*    8.55 0.00 0.00 3935 
(b) top upregulated miRNAs at day 14 
hsa-miR-21*     8.08 0.00 0.00 10890 
hsa-miR-146b    5.89 0.00 0.00 195770 
hsa-miR-21      5.49 0.00 0.00 5895379 
hsa-miR-155     5.25 0.00 0.00 33337 
hsa-miR-142-3p  4.82 0.00 0.00 99152 
hsa-miR-1185-1-3p 4.68 0.00 0.00 3420 
hsa-miR-146b*   4.04 0.00 0.00 2868 
hsa-miR-369     3.96 0.00 0.00 2836 
hsa-miR-223     3.93 0.00 0.00 76363 
hsa-miR-142-5p  3.70 0.00 0.00 134138 
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validated by qRT-PCR (fold changes of 4.3 and 5.2, respectively; P<0.001 for 
both), and these miRNAs have not been previously studied in skin inflammation.  
We also confirmed the top downregulated miRNA at day 3, miR-383 (fold change 
0.26; P<0.005), another previously understudied miRNA (Table 4.2). 
 
 
Discussion 
Among the top 10 miRNAs we found upregulated at both days 3 and 14, miR-21, 
miR-142-3p, miR-142-5p, and miR-223 have all previously been found to be 
significantly upregulated in both human and mouse DTH reactions (Vennegaard 
et al. 2012).  However, our current study had substantially higher fold changes for 
the same miRNAs than the study previously published, perhaps in part due to 
methodological differences (deep sequencing in the current vs microarray in the 
previous).  Deep sequencing not only allows for studies of differential expression, 
but also facilitates determination of nucleotide variation and discovery of novel 
miRNAs.  These four miRNAs have been shown to be related to T cells and T cell 
activation, in line with the fact that DTH reactions are mediated by T cells.  
Furthermore, upregulation of miR-223, miR-142-3p, and miR-142-5p has been 
reported in atopic dermatitis (Sonkoly et al. 2010) and in psoriasis (Zibert et al. 
2010).  miR-21 has been shown to be increased in psoriatic lesional skin, with 
evidence suggesting a causal role for this miRNA in the disease’s epidermal 
hyperplasia (Guinea-Viniegra et al. 2014).  Despite this, many of the top 
deregulated miRNAs found in our study have not previously been studied in the  
 72	  
Table 4.2: qRT-PCR confirmation of selected miRNAs in DPCP day 3 
samples vs placebo-treated skin 
microRNA fold change p-value1 
hsa-miR-503 5.2 0.0009 
hsa-miR-7 4.3 0.0006 
hsa-miR-21 1.9 0.004 
hsa-miR-383 0.26 0.001 
1paired two-tailed Student's t-test 
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context of skin biology or immunology, highlighting the emerging nature of 
miRNA research.  Our qRT-PCR data validated sequencing results both for 
miRNAs previously examined in the skin, such as miR-21, as well as for miRNAs 
that, to our knowledge, have never been described in the skin. 
 
Since our study captured miRNA profiles at three different time points 
representing distinct phases of a DTH reaction (peak, actively resolving, fully 
resolved), and because these profiles proved to be unique and not simply subsets 
of one another, they may inform on positive vs negative immune regulation in this 
human model of a DTH reaction over time.  For instance, miR-150, one of the top 
10 upregulated miRNAs at day 3 (15.71-fold), was only slightly upregulated at 
day 14 (2.96-fold).  This preferential expression of miR-150 during the peak 
reaction complements the fact that this miRNA inhibits DTH reactions in mice 
(Bryniarski et al. 2013), and therefore may need to be upregulated early on in a 
DTH reaction to promote resolution of inflammation.  Of the 8 miRNAs uniquely 
upregulated at day 14, little is known about their roles in immunology, but all 
have been implicated in decreasing cell proliferation by cancer studies (Jiang et 
al. 2014)(Uppal et al. 2015)(Liu et al. 2015)(Chen et al. 2014)(Li et al. 2013)(Li 
et al. 2012)(Jiang et al. 2015)(Gu et al. 2014).  As the day 14 reactions are 
characterized by active resolution and reduced expression of IL-2, it is possible 
that these miRNAs are related to inhibition of cell proliferation in this context as 
well.  In addition, the unique miRNA expression profiles at different time points 
may shed light on the paradoxical ability of DPCP to treat conditions of both 
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autoimmunity (alopecia areata) and ineffective immunity (melanoma and warts).  
These unique miRNA profiles are paralleled by the unique mRNA profiles we 
found at days 3 and 14 in our previous study.  Interestingly, the day 120 DPCP 
challenge biopsies, which resemble placebo-treated skin by clinical, histological, 
and gene expression criteria, do still have some miRNAs significantly upregulated 
compared to placebo-treated skin.  This may reflect persistent changes long after 
clinical resolution of induced inflammation in this DTH reaction. 
 
Certain miRNAs could account for previously identified mRNA expression 
changes, via sequence complementarity between the miRNA and mRNA.  
Nevertheless, because miRNAs can exert their effects by repressing translation 
(Fabian et al. 2010), one may not necessarily expect to see lower target mRNA 
levels for a given upregulated miRNA.  Also, the miRNA changes could be due to 
immune cell infiltration bringing in the miRNAs, and not actual deregulation 
within a given cell type.  It has been previously demonstrated that interactions 
between miRNAs and gene expression are confounded by leukocyte infiltration 
(Zhu et al. 2012), which our immunohistochemistry work has shown to be 
abundant in our samples.  One way to address this is by the technique of laser 
capture microdissection, which allows for study of specific regions or cell 
populations under microscopic visualization, and which has recently has been 
applied to psoriasis in conjunction with deep sequencing (Løvendorf et al. 2014).  
This prior study demonstrated that the top 2 upregulated miRNAs at both days 3 
and 14 (miR-223, miR-150, miR-21, and miR-146b) are all significantly 
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upregulated in reticular dermis compared to epidermis, therefore suggesting an 
immune as opposed to keratinocyte source for these miRNAs.  Although laser 
capture microdissection limits the amount of cell types being examined in a 
sample, there is still the concern that observed miRNA changes are simply due to 
infiltrating leukocytes. 
 
Since our study included inflamed biopsies at different time points, we were more 
directly able to investigate how miRNAs are modulated in leukocytes over time.  
We have shown that DPCP-challenged skin, at both days 3 and 14, contains many 
infiltrating leukocytes (including CD11c+ dendritic cells and CD3+ T cells), but 
that markers of all major defined T cell subsets including Th1 cells decrease from 
day 3 to 14.  miRNA-21, which was significantly upregulated at both days 3 and 
14, but more so at day 14 (by both sequencing and qRT-PCR), is known to 
regulate IL-12p35 expression (Lu et al. 2009) in dendritic cells (Lu et al. 2011), 
and this molecule is key to Th1 cell polarization.  Therefore, in our samples, the 
increase in miR-21 at day 3 compared to placebo-treated skin could simply be due 
to the influx of many dendritic cells expressing this miRNA.  On the other hand, 
we speculate that the increase in miR-21 expression from day 3 to 14 is due to 
actual upregulation in the infiltrating cells, and could explain the decrease in Th1 
polarization that we previously demonstrated, via decreasing IL-12p35 expression 
(Figure 4.3).  This effect may also be relevant to the therapeutic potential of this 
miRNA in psoriasis (Guinea-Viniegra et al. 2014), a disease where Th1 cells play 
an important pathogenic role.  Although previous work, including laser capture  
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Figure 4.3:  Schematic of proposed role of miR-21 in decreasing Th1 
activation during resolution of DTH reaction.  In placebo-treated skin, there 
are few CD11c+ dendritic cells and CD3+ T cells.  Three days after challenge 
with DPCP, many cells of both types infiltrate the skin, along with high 
expression of IFNγ suggestive of Th1 activation.  The observed increase in miR-
21 expression at day 3 is likely due to influx of cells expressing this miRNA.  
However, from day 3 to day 14, cellular infiltration persists and therefore the 
increase in miRNA expression between these time points may in fact be due to 
upregulation within the infiltrating dendritic cells.  miR-21 is known to decrease 
IL-12p35, and may therefore contribute to the reduced IFNγ and Th1 activation 
seen at day 14 relative to day 3, as this DTH reaction clinically resolves.  Scale 
bar = 100 µm. 
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microdissection, has implicated an immune source for the primary miRNAs we 
found to be deregulated in this DTH reaction, future studies with in situ 
hybridization will be required to determine the exact cellular sources of the 
different miRNAs.  Overall, here we provide a human antigen-specific model 
system to study miRNA regulation of a prototypic cell-mediated immune reaction 
over time, thus providing a useful starting point for the determination of roles of 
different miRNAs in positive vs negative immune regulation.
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CHAPTER 5: T CELL RECEPTOR SEQUENCING OF 
HEALTHY VOLUNTEER SKIN REACTIONS TO 
DIPHENCYPRONE 	  
 
Adaptive immune responses including DTH reactions rely on the generation of 
antigen-specific T cells, each of which has a unique rearranged T cell receptor 
(TCR).  DPCP is thought to induce DTH reactions by conjugating with 
endogenous proteins, leading to the formation of antigens that are targeted by T 
cells.  However, the specific antigen(s) involved in this process, and therefore the 
T cell clone(s) that accumulate in skin during this DTH response, are not known.  
We performed high-throughput sequencing of the entire T cell repertoire in DTH 
reactions to DPCP at different time points, in order to better understand the 
adaptive immune response that leads to the clinically observed inflammation. 
 
From 3 of the healthy volunteers’ skin biopsies which were used for mRNA and 
miRNA expression profiling, we extracted genomic DNA.  High-throughput 
sequencing of the complementarity determining region 3 (CDR3) region of the 
TCRB locus allowed for comprehensive evaluation of the T cell repertoire present 
in these human skin reactions to DPCP over time.  By looking at numbers of 
productive gene rearrangements (a strong estimate of the actual number of T cells 
sequenced in the sample), the DPCP day 3 and day 14 samples had on average 
5812 and 5056, respectively, both significantly more than the placebo (557) and 
DPCP day 120 (568) samples.  This is in agreement with CD3+ T cell counts 
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performed on these same samples by immunohistochemistry.  In parallel, numbers 
of productive unique sequences were on average highest for DPCP day 3 and day 
14 samples.  However, all samples, despite these differences in T cell counts, 
were quite diverse (low clonality values) in that they were composed of many 
different T cell clones (Table 5.1).  This suggests that DPCP is not leading to the 
formation of a single antigen to which a single unique T cell clone reacts. 
 
In addition to suggesting the presence of multiple antigens in DPCP reactions 
within individual volunteers, our data indicate that different volunteers expand 
different T cell clones.  This is supported by the fact that very few clones were 
shared among different volunteers (Figure 5.1), and that the number of clones 
expanded (as represented by numbers of productive unique sequences) varied 
among different volunteers.  This finding may have therapeutic relevance to the 
clinical efficacy of DPCP in treating cutaneous melanoma metastases, as each 
patient treated with DPCP could expand a unique repertoire of T cells targeted 
against his or her specific tumor-associated antigens. 
 
Our data also have implications for adaptive immune responses in general, 
particularly in regards to the accumulation of resident memory T cells (TRM) in 
human skin that is known to occur over time (Clark 2015).  In our study, we 
demonstrated that certain clones expand early (day 3) in skin reactions to DPCP, 
and persist over time even until day 120 when the inflammation has clinically  
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Table 5.1: Summary of TCR sequencing data. Clonality values range from 0 
(each clone appears only once) to 1 (only one clone found). 
sample type subject ID clonality 
productive unique 
sequences 
gene 
rearrangements 
placebo 006 0.2104 247 514 
placebo 013 0.0748 499 800 
placebo 015 0.1482 182 358 
placebo AVERAGE 0.1445 309 557 
DPCP day 3 006 0.0617 3975 5834 
DPCP day 3 013 0.0577 5300 7703 
DPCP day 3 015 0.0936 2569 3900 
DPCP day 3 AVERAGE 0.0710 3948 5812 
DPCP day 14 006 0.1099 3231 6181 
DPCP day 14 013 0.0882 4484 8029 
DPCP day 14 015 0.0914 548 958 
DPCP day 14 AVERAGE 0.0965 2754 5056 
DPCP day 120 006 0.0946 430 716 
DPCP day 120 013 0.0521 91 177 
DPCP day 120 015 0.2096 385 811 
DPCP day 120 AVERAGE 0.1188 302 568 
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Figure 5.1: Heat map showing similarity of sample profiles. Similarity values 
are calculated as sum of overlapping sequences divided by sum of all sequences, 
and range from 0 (no overlap) to 1 (nearly identical sample). 
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Figure 5.2: DPCP reactions induce resident memory T cells (TRM) in human 
skin.  (a) Schematic of DPCP sensitization and sample recovery.  (b) Clinical 
photos, H&E histology, and CD3+ T cell staining of the skin of healthy 
volunteers at day 3 (both placebo- and DPCP-treated), 14 (DPCP-treated), and 
120 (DPCP-treated).  Data representative of a total of 11 volunteers entered in the 
study.  (c,d) Dot plots of the frequency (number of a given sequence divided by 
the total number of sequences observed in a given sample) of TCRB CDR3 
sequences shared in placebo- or DPCP-treated skin from a representative 
individual.  (c) Clones in DPCP day 3 reactions (green, vertical axis) vs. those in 
placebo-treated skin at the same time point (red, horizontal axis).  Clones present 
in both sites are shown as blue dots.  Five clones are identified (1-5) for 
subsequent reference.  (d) Clones present in DPCP day 14 reactions (green, 
vertical axis) vs. DPCP day 120 (4 months) reactions (red, horizontal axis).  The 
same five clones (labeled and enclosed in boxes) are identified as being present in 
both samples.  (e) Quantification of the T cell clone size observed in (c) and (d) 
over time.  Each line represents one clone of five representative clones mentioned 
in (c) and (d).  From (Gaide et al. 2015). 
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Figure 5.3: TCR clone profiling during DPCP reactions over time.  (a) Skin 
samples from two different volunteers share absolutely no CDR3 sequences (left 
panel).  Within the same patient, the middle panel shows placebo-treated skin 
(red, horizontal axis), DPCP day 3 reactions (green, vertical axis), and shared 
clones (blue dots).  The right panel shows similar data, with placebo-treated skin 
again on the horizontal axis (red), DPCP day 120 (4 months) reactions on the 
vertical axis (green), and shared clones (blue).  As this technique will yield false 
negatives but not false positives, the true number of shared TCR sequences is 
likely to be higher than what is shown.  (b) Dot plots of the TCRB CDR3 
sequences shared (or not) in placebo- or DPCP-treated skin.  Several clones are 
present at high levels in all samples (blue box, a-c), whether placebo- or DPCP-
treated and irrespective of time point.  Since they are present at the four month 
time point in the skin, at high abundance, these T cells are likely to be TRM cells 
specific for an environmental antigen encountered before the trial (not DPCP).  
Several clones (green box) are undetectable in placebo-treated skin and DPCP day 
3 reaction, but present at high frequency at days 14 and 120.  These cells likely 
correspond to newly activated T cells recruited to the skin in response to DPCP.  
(c) Graphic representation of unrelated TRM clones (a-c, blue lines) and newly 
recruited clones (1-4, green lines); TCR counts are shown on the y axis, log scale.  
Clones 1-4 at day 120 also represent new TRM.  From (Gaide et al. 2015). 
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fully resolved (Figure 5.2).  Therefore, we provide the first human data following 
putative antigen-specific TRM clones over time in skin.  Other T cell clones were 
present in placebo reactions but either did not change or decreased in number over 
time, and still others did not appear until day 14 reactions after which their 
abundance decreased (Figure 5.3).  These clones do not fit the criteria of TRM 
cells, and are consistent with recent findings that only a subset of T cells in human 
skin are authentic TRM cells (Watanabe et al. 2015).  Our data were synthesized 
with work from another group using mouse models of TRM cell formation, and 
were recently published together (Gaide et al. 2015). 
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CHAPTER 6: CLINICAL AND HISTOLOGICAL 
RESPONSES OF MELANOMA PATIENTS TO 
TOPICAL DIPHENCYPRONE TREATMENT 	  	  
We enrolled 6 patients in our trial using topical DPCP to treat cutaneous 
melanoma metastases.  Each patient had unique treatment histories prior to 
entering our trial, but all were successfully sensitized to DPCP, and received at 
least 3 weeks of twice weekly DPCP treatment applications to their cutaneous 
metastases. 
 
Patient 001 was a 52-year-old female who, 23 months prior to beginning DPCP 
treatment, was diagnosed with a 1.5 mm high-risk (mitotic rate of 4) melanoma of 
the right temple with associated lymphovascular invasion, which was treated with 
wide local excision and negative sentinel node biopsy.  3 months later, she 
developed multiple satellite metastases, and 2 months after that, underwent 
radiation therapy.  This was followed by ipilimumab and topical imiquimod the 
next month.  4 months after that, the patient received systemic IL-2 therapy (16 
doses), with an additional course of IL-2 2 months later (8 doses).  She underwent 
an additional course of ipilimumab, which was complicated by colitis requiring 
the use of infliximab.  Her cutaneous lesions were controlled with the use of 
repeated cryotherapy and sustained topical imiquimod.  She began temozolomide 
therapy 2 months before enrolling in our trial.  Despite her multiple therapies, the 
patient continued to have advanced unresectable cutaneous melanoma that was 
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distributed in her right ear and right cheek and scalp area, and thus her oncologist 
referred her to our trial at The Rockefeller University. 
 
After completing screening for our trial, the patient had 2 biopsies: one at the site 
of one of her cutaneous metastases, and one at a site of normal skin.  Sensitization 
was mildly successful, with only 1 of 3 sensitization sites (the right upper arm) 
having a response, and that response was weak (erythema and induration both 
scored as 1, size 2 x 1.5 mm).  DPCP, at the concentration (0.04%) that elicited 
robust inflammation in our healthy volunteers, was applied to her cutaneous 
metastases twice weekly for 3 weeks, but the induced inflammation continued to 
be weak with only mild erythema observed.  A biopsy was taken of a melanoma 
metastasis 3 weeks into the course of treatment.  By CD3 immunohistochemistry 
of biopsy tissue, the melanoma lesion biopsied before commencing DPCP 
treatment had more CD3+ T cells than the lesion biopsied 3 weeks into treatment 
(Figure 6.1).  Repeat skin biopsy the month after entering our trial revealed the 
presence of a BRAF mutation (her original BRAF typing was done on her 
primary tumor, with no mutation found), and so the patient started vemurafenib 
therapy the following month, thus discontinuing DPCP therapy after 3 weeks of 
treatment.  This patient left our study before definitive assessment of clinical 
response (tumor regression) to DPCP could be ascertained, but our experience 
with her prompted us to add flexibility to our protocol in terms of the 
concentration of DPCP that could be used for future patients.  It is likely that  
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Figure 6.1: Patient 001 only exhibited mild inflammation in response to the 
concentration of DPCP that led to robust inflammation in our healthy 
volunteers.  Clinical photography and CD3 immunohistochemistry below of 
patient 001 before topical DPCP applications (left) and 3 weeks into topical 
DPCP applications (right).  Scale bar = 100 µm. 
 
CD3
before DPCP 3 weeks DPCP
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melanoma patients such as this have systemic immunosuppression that may 
diminish their immune responses generated by DPCP applications. 
 
Patient 002 was a 98-year-old male who, 4 years prior to beginning DPCP 
treatment, was diagnosed with a melanoma lesion of the chest, which was treated 
with surgical excision.  Two more recurrences occurred in the following years, 
both also treated with surgical excision.  Then a further recurrence occurred, now 
with many melanoma lesions on the chest.  This was treated with 2 months of 
topical imiquimod without response, and so the patient was referred to our trial at 
The Rockefeller University. 
 
After completing screening for our trial, the patient had 2 biopsies: one at the site 
of one of his cutaneous metastases, and one at a site of normal skin.  Sensitization 
was successful, and applications of DPCP to cutaneous metastases continued 
twice weekly for 7 weeks.  A biopsy was taken of a melanoma metastasis both 3 
weeks and 7 weeks into the course of treatment.  Unlike patient 001, this patient 
exhibited robust clinical inflammation in response to DPCP, and 
immunohistochemistry of biopsy tissue for CD3 showed increased T cells upon 
DPCP treatment.  Patient 002 also demonstrated partial tumor regression, as 
evidenced by immunohistochemistry for the melanoma marker MLANA, within 7 
weeks of starting treatment (Figure 6.2).  Sadly, after 7 weeks on treatment, the 
patient passed away from what we believe are natural causes/medical problems 
unrelated to his melanoma or its treatment. 
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Figure 6.2: Patient 002 exhibited robust inflammation and partial melanoma 
regression in response to DPCP.  Clinical photography as well as specified 
histological stains below of patient 002 before topical DPCP applications (left) 
and 7 weeks into topical DPCP applications (right).  Scale bar = 100 µm. 
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Patient 003 was a 91-year-old female who, 59 months prior to beginning DPCP 
treatment, was diagnosed with a 1.8 mm non-ulcerated melanoma of the pretibial 
region, which was treated with wide excision/split thickness skin graft.  11 
months later, a small focus of local recurrence appeared at the edge of the split 
thickness skin graft, which was treated with wide excision.  24 months after that, 
a further area of local recurrence appeared that initially responded well to 
imiquimod.  However, 22 months later (2 months before beginning DPCP 
treatment), the patient developed progressive low-volume local recurrence (two 
pigmented metastasis lesions, each about 5 mm in diameter, Figure 6.3), which 
was unresponsive to imiquimod and the patient declined surgery due to previous 
difficulty with healing.  At the recommendation of her oncologist, the patient 
entered our trial at The Rockefeller University. 
 
After completing screening, the patient had 2 biopsies: one at the site of one of 
her cutaneous metastases, and one at a site of normal skin.  After successful 
sensitization, applications of DPCP to cutaneous metastases occurred twice 
weekly for 14 weeks (98 days, the full course of DPCP treatment specified in our 
clinical protocol), at which point the patient’s left lower leg was very inflamed 
and therefore it was impossible to see whether melanoma lesions were present or 
not (Figure 6.4).  One biopsy was taken at this time (day 98) of an inflamed skin 
site that was not previously involved with melanoma.  We then examined the 
patient at day 128 (with no DPCP being applied since day 98), and the 
inflammation largely subsided, thus allowing us to see that the melanoma 	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Figure 6.3: Patient 003 exhibited full clinical and histological melanoma 
metastasis regression upon DPCP treatment.  Skin photography, with 
immunohistochemistry for melanocyte marker MLANA below, of the patient’s 
left lower leg before DPCP application (left) and after 14 weeks of twice weekly 
DPCP applications (right).  Brown staining in histological image at right likely 
represents melanophages.  There were two melanoma metastases visible before 
DPCP application, and their locations are indicated by arrows (the thick arrow 
shows the site that was biopsied).  Scale bar = 100 µm.	  
before DPCP after DPCP
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Figure 6.4: Skin photography of patient 003’s left lower leg at end of DPCP 
applications (day 98, after 14 weeks of twice weekly applications).  The skin was 
inflamed to the point that it was not possible to determine whether the patient’s 
melanoma lesions were still present.  Therefore, the patient discontinued DPCP 
treatment at this time and returned 30 days later (day 128) for the photograph 
shown in Figure 6.3. 
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metastases were clinically resolved (Figure 6.3).  One biopsy was performed of a 
resolved lesion (at a site previously involved with melanoma).  We confirmed the 
absence of melanoma cells by immunohistochemistry for MLANA (Figure 6.3).  
The patient was seen for follow-up visits 1 month after and 4 months after the day 
128 visit, and appeared well both times with no cutaneous metastases visible. 
 
Patient 004 was a 93-year-old male who, 10 years prior to beginning DPCP 
treatment, was diagnosed with a melanoma on his right foot, which was treated 
surgically.  5 years later, after spread had occurred, the patient received imatinib 
(4 injections every 3 weeks for 9 weeks), which resulted in complete remission 
lasting 3 years.  After those 3 years, another round of imatinib was received with 
complete remission once again, but this time only lasting for 6 months.  1 year 
prior to beginning DPCP treatment, the patient completed a course of ipilimumab 
(4 doses spaced 3 weeks apart), which did not result in any response.  The patient 
then began a third round of imatinib, which also did not result in any response.  At 
this point the patient had many cutaneous melanoma metastases on his right 
anterior thigh, along the shin, and behind the knee, and this is when he was 
referred to our trial at The Rockefeller University. 
 
This patient followed a unique clinical course that allowed us to	  evaluate 
melanoma regression in response to DPCP, PD-1 checkpoint inhibitor therapy 
(now considered the standard of care treatment for metastatic melanoma; see 
(Ribas et al. 2015)), and a combination of the two.  After completing screening, 
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the patient had 2 biopsies: one at the site of one of his cutaneous metastases, and 
one at a site of normal skin.  After successful sensitization, applications of DPCP 
to cutaneous metastases occurred twice weekly for 9 weeks.  During this time 
period, strong inflammation was induced by DPCP as expected, and some lesions 
disappeared or shrank, but some new ones also appeared (Figure 6.5).  Therefore, 
the efficacy of DPCP alone to regress melanoma was difficult to assess.  A biopsy 
was taken of a melanoma metastasis both 3 weeks and 9 weeks into the course of 
treatment.  After these 9 weeks, the patient left our trial because his oncologist 
wanted to prescribe the (at the time not FDA approved) PD-1 checkpoint inhibitor 
nivolumab, of which he began receiving infusions every 3 weeks.  3 months later, 
since the patient was not responding to nivolumab (which at that time became 
FDA approved), his oncologist recommended he restart DPCP treatment (twice 
weekly) in conjunction with nivolumab, which the patient continued to receive 
every 3 weeks.  Since we were unsure of how these two immunomodulatory 
agents would interact with each other (i.e. there was concern for too robust an 
immune reaction), we started by only treating a select area of skin with topical 
DPCP.  After 1 month of this, the patient tolerated the dual treatment well and 
showed tumor regression in the select DPCP-treated area.  Therefore, we 
expanded the DPCP treatment field to include all of the patient’s cutaneous 
metastases, and this expanded the regression response to a wider region (Figure 
6.6).  The patient received this dual therapy for 7 months, with a biopsy taken of a 
cutaneous metastasis at 1 month, as well as biopsies of both a cutaneous 
metastasis and nearby uninvolved (but inflamed due to treatment) skin taken at 7 	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Figure 6.5: Patient 004 exhibited melanoma metastasis regression upon 
DPCP treatment alone, but new lesions also developed.  Skin photography of 
the patient’s right anterior thigh before topical DPCP applications (left) and 9 
weeks into topical DPCP applications (right). 
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Figure 6.6: Patient 004 exhibited widespread melanoma metastasis 
regression upon combined DPCP and PD-1 checkpoint inhibitor therapy.  
Skin photography of the patient’s right anterior thigh before restarting topical 
DPCP applications but having been on PD-1 checkpoint inhibitor nivolumab for 3 
months (left), 1 month into combined nivolumab and topical DPCP therapy (only 
to boxed area) (middle), and 4 months into combined nivolumab and topical 
DPCP therapy (applied throughout) (right). 
 
 
 
 
 
 
 
PD-1 inhibitor
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months.  After these 7 months, although many of the patient’s lesions regressed, it 
became more difficult for him to tolerate DPCP applications to the large areas of 
skin (with resultant extensive inflammation) that were involved with melanoma, 
and so he elected to discontinue DPCP treatment (but still continued nivolumab 
treatment).  During this patient’s dual treatment, we observed patches of skin on 
the leg not involved with melanoma to be affected with vitiligo (Figure 6.7), 
suggesting a loss of pigment-producing cells distant from the site of DPCP 
application, that presumably are targeted by the immune system along with 
melanoma cells.  This is in line with previous reports showing that DPCP leads to 
vitiligo (Pires et al. 2010). 
 
Patient 005 was a 66-year-old male who, 16 months prior to beginning DPCP 
treatment, was diagnosed with a 2.1 mm melanoma on the left forehead, which 
was treated surgically.  He was diagnosed with a new focus of melanoma medial 
to the scalp scar 7 months later, and received 3600 centiGray of adjuvant radiation 
in 6 doses.  In the following months, he developed multiple foci of cutaneous 
metastases in the scalp, and was treated with both cryotherapy and topical 
imiquimod.  The patient was applying imiquimod daily to only part of his scalp, 
and this began 2 months prior to entering our trial, with resultant mild erythema.  
However, many cutaneous metastases persisted, and so the patient was referred to 
our trial at The Rockefeller University, while still receiving topical imiquimod 
applications. 
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Figure 6.7: Patient 004 exhibited vitiligo at skin sites distant from DPCP 
applications.  Skin photography of the patient’s left anterior thigh (as opposed to 
right anterior thigh which was involved with melanoma) before starting topical 
DPCP applications (left) and 3 months into combined nivolumab and topical 
DPCP therapy (right). 
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After completing screening, the patient had 3 biopsies: one at the site of one of his 
cutaneous metastases, one at a site of normal skin, and one at an area of skin 
treated with topical imiquimod (treatment had been ongoing for 2 months).  After 
successful sensitization, applications of DPCP to cutaneous metastases occurred 
twice weekly for 7 weeks, only to the metastases not already being treated with 
imiquimod (which continued).  A biopsy was taken of a DPCP-treated melanoma 
metastasis both 3 weeks and 7 weeks into the course of treatment.  As imiquimod, 
like DPCP, acts through the immune system, we elected to perform a biopsy of 
imiquimod-treated skin, so that we could compare it to a biopsy of DPCP-treated 
skin from the same patient.  This revealed increases in various immune cell types 
in DPCP-treated compared to imiquimod-treated skin, including: CD3+ T cells, 
CD8+ cytotoxic T cells, CD11c+ myeloid dendritic cells, and CD163+ 
macrophages (Figure 6.8).  Furthermore, by qRT-PCR analysis, DPCP induced 
stronger upregulation of IFNγ (3-fold) and IL-9 (5-fold) than imiquimod.  During 
the 7 weeks of DPCP treatment, many of the patient’s cutaneous metastases 
became lighter and/or smaller, with histological evidence of melanoma regression 
along with inflammation (Figure 6.9).  However, the patient unfortunately 
developed internal metastases at this point, and so elected to leave our trial and 
begin ipilimumab treatment. 
 
Patient 006 was an 81-year-old female who, 18 months prior to beginning DPCP 
treatment, was diagnosed with a melanoma on the right lower calf, which was 
treated surgically.  Then the patient developed many small metastatic melanoma 
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Figure 6.8: In patient 005, DPCP induced stronger histological inflammation 
than imiquimod.  Specified histological stains of biopsies from patient 005 of 
skin treated with imiquimod (left) and DPCP (right). 
imiquimod DPCP
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Figure 6.9: Patient 005 exhibited robust inflammation and partial melanoma 
regression in response to DPCP.  Clinical photography as well as specified 
histological stains below of patient 005 before topical DPCP applications (left) 
and 7 weeks into topical DPCP applications (right).  Green box indicates area of 
imiquimod application (commenced 2 months prior to DPCP applications).  Scale 
bar = 100 µm. 
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Figure 6.10: Patient 006 exhibited nearly complete clinical melanoma 
metastasis regression upon DPCP treatment.  Skin photography of the patient’s 
right lower calf before DPCP application (left) and after 14 weeks of twice 
weekly DPCP applications (right).  
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lesions on her right lower calf, and so was referred to our trial at The Rockefeller 
University. 
 
After completing screening, the patient had 2 biopsies: one at the site of one of 
her cutaneous metastases, and one at a site of normal skin.  After successful 
sensitization, applications of DPCP to cutaneous metastases occurred twice 
weekly for 14 weeks (98 days, the full course of DPCP treatment specified in our 
clinical protocol), at which point the patient’s right lower calf was very inflamed 
and therefore it was impossible to see whether melanoma lesions were present or 
not.  A biopsy was taken of a melanoma metastasis both 3 weeks and 9 weeks into 
the course of treatment.  We then examined the patient at day 128 (with no DPCP 
being applied since day 98), and the inflammation largely subsided, thus allowing 
us to see that, while most metastases regressed, two small lightly pigmented 
lesions remained in the treated area (Figure 6.10).  One biopsy was performed of 
each of these lesions, with site #1 referring to the superior and site #2 referring to 
the inferior.  The results from these biopsies will be discussed in the following 
chapter, wherein mechanistic studies on the biopsy specimens from all 6 patients 
are presented. 
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CHAPTER 7: MECHANISTIC STUDIES OF IMMUNE-
MEDIATED MELANOMA METASTASIS 
REGRESSION INDUCED BY DIPHENCYPRONE 
 
To better ascertain the mechanisms involved in immune-mediated tumor 
regression induced by DPCP, we studied biopsy tissues from our 6 patients at 
various time points.  In line with our healthy volunteer data, DPCP applications in 
melanoma patients led to extensive immune cell infiltrates, including CD3+ T 
cells, CD11c+ myeloid dendritic cells, and CD163+ macrophages, both after a 
single and repeated applications.  These infiltrates persisted in follow-up biopsies 
performed 30 days after cessation of DPCP treatment (Figure 7.1).  In addition to 
these cells, which are presumably integral to immune-mediated anti-melanoma 
responses, we found that DPCP application led to increases in granulysin.  By 
two-color immunofluorescence, granulysin co-localized with NKp46+ natural 
killer cells more than CD8+ cytotoxic T cells (Figure 7.2). 
 
In an effort to obtain a more specific understanding of the kind of immune 
response that may lead to tumor regression, we determined the evolving T cell 
polarization in this repeated DPCP application scenario.  Our work with healthy 
volunteers demonstrated that gene expression markers of all major T cells subsets 
(Th1, Th2, Th9, Th17, Th22, and regulatory T cells) all significantly increase at 3 
days following a single application of DPCP.  With our melanoma patients, we 
similarly obtained biopsies of a normal skin site 3 days following a single 
application of DPCP.  However, with these patients, we also obtained biopsies of  
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Figure 7.1: Histological analysis of biopsy samples indicates that DPCP leads 
to extensive immune cell infiltrates both after a single and repeated 
applications, and that these infiltrates persist for at least 30 days following 
cessation of DPCP application.  Shown are H&E staining and 
immunohistochemistry for T cell marker CD3, myeloid dendritic cell marker 
CD11c, and macrophage marker CD163, on: (a) peri-lesional skin before DPCP 
treatment, (b) melanoma metastasis before DPCP treatment, (c) peri-lesional skin 
3 days after first DPCP application, (d) peri-lesional skin at end of DPCP 
applications (day 98, after 14 weeks of twice weekly applications), and (e) 
melanoma metastasis 30 days after DPCP applications concluded (day 128).  
Biopsies from patient 003 are shown.  Scale bar = 100 µm. 
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Figure 7.2: Two-color immunofluorescence demonstrates co-localization of 
granulysin with natural killer cells more than cytotoxic T cells during and 
following DPCP treatment.  Shown are granulysin (red)/CD8 (green) (top) and 
granulysin (red)/NKp46 (green) (bottom) immunofluorescence on: (a) peri-
lesional skin before DPCP treatment, (b) melanoma metastasis before DPCP 
treatment, (c) peri-lesional skin 3 days after first DPCP application, (d) peri-
lesional skin at end of DPCP applications (day 98, after 14 weeks of twice weekly 
applications), and (e) melanoma metastasis 30 days after DPCP applications 
concluded (day 128).  Biopsies from patient 003 are shown.  Scale bar = 100 µm. 
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skin sites after repeated (twice weekly) DPCP applications (the number of 
applications varied among patients, as discussed in Chapter 6).  The study of 
repeated DPCP applications is clinically relevant as this is what is traditionally 
required when DPCP is used as a treatment, whether for cutaneous melanoma 
metastases (Damian et al. 2014), alopecia areata (Ohlmeier et al. 2012), or warts 
(Buckley et al. 1999).  By qRT-PCR analysis of paired single and repeated DPCP 
application biopsy sites from the 6 melanoma patients, we found that expression 
of Th1-related genes (IFNG, CXCL9, CXCL10, and CXCL11) generally 
increased with repeated applications, while markers of all other major T cell 
subsets (Foxp3, IL4, IL13, IL9, IL17A, and IL22) decreased (Figure 7.3).  IL9 
expression was significantly increased in single compared to repeated DPCP 
applications, and this may be necessary for production of other pro-inflammatory 
cytokines including IFNG (Schlapbach et al. 2014).  Th1-related genes IFNG and 
CXCL9 were, on the other hand, significantly increased in repeated compared to 
single DPCP applications, and this overall shift towards Th1 polarization would 
be expected to promote anti-neoplastic effects (Braumüller et al. 2013).  These 
findings, along with the increasing numbers of natural killer cells (Figure 7.2), 
reaffirm the utility of repeated DPCP applications in melanoma treatment. 
 
As described in Chapter 6, patient 006 had two small lightly pigmented lesions 
remaining on her skin following DPCP treatment.  Both of these lesions were  
 
 
 110	  
Figure 7.3: Repeated DPCP applications leads to shift towards Th1 
polarization.  Each chart shows normalized gene expression values measured by 
qRT-PCR, and each line represents 1 of the 6 melanoma patients.  IFNG, CXCL9, 
Foxp3, IL4, IL13, and IL9 were all significantly different (p<0.05) between single 
and repeated DPCP applications by paired Student’s t-test. 
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Figure 7.4: Successfully regressed melanoma metastasis compared to one 
that did not from the same patient shows increased Th1 polarization.  (a) 
Skin photography showing both lightly pigmented lesions that remained on 
patient 006’s skin following DPCP treatment, with arrows pointing to 
corresponding histology images taken from biopsy tissue.  (b) Normalized qRT-
PCR gene expression measures for various molecules defining different T cell 
subsets. 
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biopsied, and only one of the two had MLANA+ melanoma cells.  Therefore, the 
other lesion was likely pigmented in appearance due to the presence of 
melanophages which had ingested melanin pigment, and was therefore an 
example of successful immune-mediated metastasis regression.  Although this is 
only a single case, we examined both of these biopsies in an attempt to ascertain 
the differences between a successfully regressed melanoma metastasis and one 
that did not from the same patient.  More CD3+ T cells were observed in the 
successfully regressed metastasis, along with stronger Th1 polarization (Figure 
7.4), in agreement with our hypothesis that Th1 polarization promotes melanoma 
regression.  Future study of additional patients (both responders and non-
responders to DPCP) will likely provide valuable insight into the roles played by 
different immune cell subsets in promoting tumor regression. 
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CHAPTER 8: GENERAL DISCUSSION 	  
Spontaneous regression of metastatic melanoma occasionally occurs, therefore 
suggesting a role for immune mechanisms in the control of this disease 
(McGovern 1975), and the clinical condition vitiligo provides evidence for the 
potential of immune attack against melanocytes.  We have previously 
demonstrated the presence and potential functional role of dendritic cells in 
pigmented lesion pathogenesis (Gulati et al. 2015), thus further highlighting the 
role of immunosurveillance in melanoma.  The FDA has recently approved 
antibodies that act by inhibiting two different immune checkpoints: cytotoxic T 
lymphocyte-associated antigen 4 (CTLA-4) and programmed cell death protein 1 
(PD-1) (Postow et al. 2015a). 
 
Another emerging therapeutic approach in melanoma (but not currently approved 
by the FDA), also in the realm of immunotherapy, is the contact sensitizer 
diphencyprone (DPCP).  Compared to immune checkpoint inhibitors, DPCP has 
the advantages of lower price (being an easily produced hapten as opposed to an 
antibody) and favorable safety profile (the main toxicity being the expected 
inflammatory reaction).  DPCP has recently been used in a 50-patient case series 
of cutaneously metastatic melanoma, with 46% of patients having complete 
clearance of their disease, and a further 38% having partial clearance (Damian et 
al. 2014), but corresponding study of the immune response to DPCP was not 
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conducted.  We studied immune reactions to DPCP, first in healthy volunteers and 
then in melanoma patients, to better understand the immune mechanisms 
underlying this anti-tumor response. 
 
Several immune pathways that we found to be induced by DPCP in healthy 
volunteer normal skin might mediate this anti-melanoma response.  First, we 
identified significant up-regulation of IL-24 mRNA, which is a cytokine with 
established anti-melanoma activity (Jiang et al., 1995).  Since this cytokine was 
up-regulated only transiently (peak at day 3, but resolved at day 14), it could 
indicate the need for chronic/repeated application of DPCP to maintain effector 
cytokines for tumor responses.  Furthermore, we observed strong increases in 
IFNγ expression and this cytokine enhances antigen presentation potential, is anti-
proliferative for many cell types (Braumüller et al., 2013), and its induced 
molecule CXCL10 has anti-melanoma activity (Antonicelli et al., 2011).  Another 
cytokine we found to be upregulated by DPCP, IL-9, has recently been linked to 
melanoma regression (Purwar et al., 2012).  In addition to these cytokines with 
potential anti-neoplastic effects, DPCP use resulted in many infiltrating CD8+ 
cells, along with increased granzyme B and granulysin expression, and these 
would be probable cytotoxic effectors.  Granulysin has been shown to promote 
chemotaxis of CD4+ T cells in addition to its cytolytic properties (Deng et al., 
2005), and both of these functions may contribute to the peak DTH response 
considering we observed granulysin expression on both CD8+ and CD8- T cells.  
We also noted a marked increase in DCs and especially DC-LAMP+ mature DCs, 
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that could provide a local environment to increase antigen presentation of tumor 
antigens (immature DCs, in the absence of appropriate co-stimulation, present 
antigens in a tolerogenic fashion), as well as XCR1+ DCs, which have a role in 
antigen cross-presentation (Kroczek and Henn, 2012).   
 
We also examined the potential roles of miRNAs in healthy volunteer skin 
reactions to DPCP, as they may be involved in its therapeutic applications.  
Among the top 10 miRNAs we found upregulated at both days 3 and 14, miR-21, 
miR-142-3p, miR-142-5p, and miR-223 have all previously been found to be 
significantly upregulated in both human and mouse DTH reactions (Vennegaard 
et al. 2012).  These four miRNAs have been shown to be related to T cells and T 
cell activation, in line with the fact that DTH reactions are mediated by T cells.  
Despite this, many of the top deregulated miRNAs found in our study have not 
previously been studied in the context of skin biology or immunology, 
highlighting the emerging nature of miRNA research.  Our qRT-PCR data 
validated sequencing results both for miRNAs previously examined in the skin, 
such as miR-21, as well as for miRNAs that, to our knowledge, have never been 
described in the skin.  The unique miRNA expression profiles at different time 
points may shed light on the paradoxical ability of DPCP to treat conditions of 
both autoimmunity (alopecia areata) and ineffective immunity (melanoma and 
warts).  These unique miRNA profiles are paralleled by the unique mRNA 
profiles we found at days 3 and 14 via microarray analysis. 
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Our TCR sequencing data from the healthy volunteer study demonstrated that 
these DTH reactions are polyclonal, and therefore suggests that the induced 
inflammation is not due to a single antigen.  Also, different individuals expanded 
different T cell clones in response to the same application of DPCP, which could 
mean that DPCP is conjugating with unique proteins in each person.  This may 
have relevance to the action of DPCP in melanoma patients, as each treated 
patient may expand a unique repertoire of T cells specific to antigens found only 
in that patient.  Another way to interpret these data is that DPCP application leads 
to the formation of one or few antigens, but then many other T cell clones with 
various antigen specifities are non-specifically recruited to the site, due to release 
of chemokines and other inflammatory mediators.  It is known that the tissue 
damage and inflammation that occur during an immune response can lead to the 
release of epitopes from injured tissue which act as antigens, in a process known 
as antigen or epitope spreading (Vanderlugt and Miller 2002).  Our TCR 
sequencing data demonstrated the appearance of new T cell clones at 14 days (but 
not 3 days) after DPCP challenge (Figure 5.3), and these may represent newly 
recruited clones which migrated to the skin due to antigen spreading.  This 
phenomenon of antigen spreading has been shown to promote anti-tumor 
vaccination responses and occurs in melanoma patients (Hu et al. 2014).  
Vaccination of a melanoma patient with antigenic peptides MAGE-A3 and 
MAGE-A1 led to the expansion of T cell clones targeting antigens not present in 
the vaccine, including one clone that was not present in the patient’s blood or 
cutaneous metastases prior to vaccination.  This clone, which was able to lyse 
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autologous tumor cells in vitro, targeted the mutated (but not wild-type) form of a 
protein called caseinolytic protease P (CLPP) present in this particular patient, a 
mutation not commonly found in other melanoma patients (Corbière et al. 2011).  
These results provide demonstration of antigen spreading in cancer 
immunotherapy, and also highlight the potential clinical utility of targeting 
antigens not classically associated with melanoma, which may occur upon DPCP 
application. 
 
Overall, this work with healthy volunteers formed a basis for investigating 
specific immune elements that may be induced in melanoma lesions that are 
treated with DPCP, as well as the baseline immune competence of cancer patients.  
It also led to insights regarding the regulation of immune responses, and provides 
a useful comparison point to inflammatory skin diseases such as psoriasis.  
Furthermore, due to our inclusion of a late time point (day 120) representing a 
fully resolved inflammatory reaction, our samples capture the tissue-resident 
memory T cells that are known to accumulate in skin over time (Clark 2015).  Our 
TCR sequencing data demonstrated that certain T cell clones expand early (day 3) 
in skin, and persist over time even until day 120.  Therefore, we provided the first 
human data following putative antigen-specific resident memory T cell clones 
over time in skin (Gaide et al. 2015). 
 
The specific mechanisms of DPCP within melanoma treatment are largely 
unknown.  One study showed (paradoxical) decreases in IL-17 family cytokines 
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in regressed lesions, possibly because the biopsy may not have been done at a 
time of active DPCP-induced inflammation.  There was an increase in CTLA-4 
and CD27 expression, which could indicate T cell activation by DPCP.  However, 
other activation pathways were not explored (Martiniuk et al. 2010).  Although 
our healthy volunteer study generated much data informing on potential anti-
neoplastic effects of DPCP, a trial with actual melanoma patients was needed to 
better understand mechanisms of DPCP-mediated tumor regression, as well as 
potential toxicity that may be induced in these patients.  We utilized the same 
topical DPCP formulation on both healthy volunteers and melanoma patients, but 
the latter often required higher concentrations of DPCP in order to achieve the 
same inflammatory response.  This suggests a baseline immunosuppression in 
these patients.  Although our patients’ skin metastases often had infiltrating T 
cells at baseline (before DPCP applications), these may represent exhausted T 
cells which are known to infiltrate melanoma metastases, but whose functional 
deficiency is reversible (Baitsch et al. 2011).  Future work will characterize how 
molecules of the exhausted T cell phenotype are modified by DPCP, and how 
positive vs negative immune regulation changes in tumors upon treatment. 
 
Our clinical trial with metastatic melanoma patients allowed us to more directly 
study the immunologic mechanisms underlying the efficacy of DPCP to treat skin 
metastases.  Six patients were enrolled in the study, and although each had a 
unique treatment course, 5 demonstrated at least partial melanoma regression in 
response to DPCP treatment, with only patient 001 having an indeterminate 
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outcome (due to her leaving the study after only 3 weeks of treatment).  Our study 
was limited by a small sample size with several confounding factors including 
varied treatment histories.  Recent FDA approval of several agents for metastatic 
melanoma treatment while we were conducting our clinical trial (Figure 1.1) 
decreased the pool of patients referred to our trial.  Despite this, by studying the 6 
patients together, several general principles emerged.  First, DPCP led to 
increases in several cell types that are likely integral to immune-mediated tumor 
regression, including T cells, myeloid DCs, macrophages, and natural killer cells 
(which co-localized with granulysin).  Since we took skin biopsies of DPCP-
treated skin both at 3 days after a single challenge (similar to as was done with the 
healthy volunteers), and after many repeated challenges (as is generally done 
when DPCP is used clinically), we were able to examine the differences between 
these two immune reactions.  We observed significant increases in Th1-defining 
molecules in repeated vs. single applications, with parallel decreases in molecules 
defining other T cell subsets (Th2, Th9, Th17, Th22, and regulatory T cells).  This 
shift towards Th1 polarization is likely relevant to melanoma treatment, as these 
cells have established roles in anti-melanoma responses.  To further support this, 
our patient with both a regressing and non-regressing metastasis in response to 
DPCP had increased expression of Th1-defining molecules in the former. 
 
Since one of our patients was receiving topical imiquimod upon entering our trial, 
we had the opportunity to biopsy a site treated with this immunomodulatory 
compound, and to compare it to topically applied DPCP.  Imiquimod signals to 
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the innate immune system through toll-like receptor 7, and therefore has a distinct 
mechanism of action to DPCP, which acts through the adaptive immune system.  
By gene expression analysis of skin biopsy specimens, immune reactions to these 
two agents were in fact distinct, with higher IFNγ expression in DPCP-treated 
skin.  Also in the realm of immunotherapy, one of our patients received the PD-1 
inhibitor nivolumab, which acts by inhibiting a negative regulator of immune 
responses.  As such, we were able to obtain preliminary data regarding the 
potential synergy between these two treatments.  It has been recently 
demonstrated that tumor regression with PD-1 inhibition requires pre-existing 
CD8+ T cells that are negatively regulated by the PD-1/PD-L1 axis (Tumeh et al. 
2014).  Since our data have shown that DPCP leads to increases in CD8+ T cells 
as well as PD-1, PD-L1, and PD-L2, DPCP is likely to increase the clinical 
efficacy of PD-1 inhibition.  This may be a therapeutic avenue of interest in the 
future, as both PD-1 inhibitors and DPCP act on the immune system but in 
different ways, and PD-1 inhibitors have recently emerged as the standard of care 
treatment for metastatic melanoma.  Our patient was having minimal regression of 
his bulky cutaneous metastases while solely on nivolumab, but demonstrated 
dramatic regression when topical DPCP applications were added in conjunction.  
This supports the hypothesis that these two therapies would complement each 
other, but a larger trial with more patients is needed.   
 
Overall, the work contained herein provides varied insights into cutaneous 
immune responses through the use of DPCP, a prototypic cause of DTH reactions, 
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and examines how they can be successfully employed in the context of melanoma 
therapy.
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